PROMPT ENGINEERING FOR TRANSFORMER-BASED CHEMICAL SIMILARITY SEARCH IDENTIFIES STRUCTURALLY DISTINCT FUNCTIONAL ANALOGUES

© Clayton W. Kosonocky Department of Molecular Biosciences The University of Texas at Austin clayton.kosonocky@utexas.edu

© Claus O. Wilke* Department of Integrative Biology The University of Texas at Austin wilke@austin.utexas.edu O Aaron L. Feller Department of Molecular Biosciences The University of Texas at Austin aaron.feller@utexas.edu

O Andrew D. Ellington Department of Molecular Biosciences The University of Texas at Austin ellingtonlab@gmail.com

ABSTRACT

Chemical similarity searches are widely used in-silico methods for identifying new drug-like molecules. These methods have historically relied on structure-based comparisons to compute molecular similarity. Here, we use a chemical language model to create a vector-based chemical search. We extend implementations by creating a prompt engineering strategy that utilizes two different chemical string representation algorithms: one for the query and the other for the database. We explore this method by reviewing the search results from five drug-like query molecules (penicillin G, nirmatrelvir, zidovudine, lysergic acid diethylamide, and fentanyl) and three dye-like query molecules (acid blue 25, avobenzone, and 2-diphenylaminocarbazole). We find that this novel method identifies molecules that are functionally similar to the query, indicated by the associated patent literature, and that many of these molecules are structurally distinct from the query, making them unlikely to be found with traditional chemical similarity search methods. This method may aid in the discovery of novel structural classes of molecules that achieve target functionality.

Keywords Drug Discovery · Machine Learning · Chemical Similarity Search · Prompt Engineering · SMILES

1 Introduction

Applications for small molecules in modern society are various and widespread, including treatment of heritable disease, pathogen inhibition, and the generation of functional materials for use in electronics and consumer goods. Molecular function emerges from structure, but it is not always obvious how this emerges from first principles due to the dependence of function on the target molecule [1]. Traditionally, exploration of natural products has led to the identification of vital pharmaceuticals and specialty chemicals [2–5]. These first generation molecules act as starting points, upon which new molecules are engineered for furthering desired functionality [6]. Structural neighbors often share similar functionality, as the relevant chemistry may be unchanged or improved [7]. However, molecules with low structural similarity can act on the same target despite the highly different structure, as is the case with morphine and fentanyl on the μ -opioid receptor [8].

There are numerous contemporary approaches to applying machine learning to chemistry [9–16]. However, the application of language models to this space has led to surprising success in predicting biochemical features such as drug-likeness and protein-ligand interactions [11, 13]. These methods require string representations of molecules, commonly using the Simplified Molecular-Input Line-Entry System (SMILES) [17]. Language models are often

^{*}Corresponding Author

trained in an unsupervised manner with the reward function tied to sequence reconstruction, i.e. feeding the model a masked or partial input with the goal of reconstructing the original sequence. It was recently demonstrated that a chemical language model, though trained only on SMILES strings, correctly predicted complex biophysical and quantum-chemical properties [18]. This points to the possibility that these models develop a chemical latent space that allows for the emergence of higher-order biochemical comprehension.

Recently, computationally generated chemical libraries have grown to surpass 37 billion commercially available compounds [19]. This marked growth has generated a new field of computational pre-screening of chemicals in order to support resource efficient discovery in the laboratory [20]. One primary class of computational pre-screening methods are chemical similarity searches. These methods have historically used structure-based comparisons, a notable example being the fingerprint Tanimoto search which computes a hierarchical list of molecules ranked by molecular substructure similarity to a given query [21, 22].

Chemical Language Models (CLM) have been applied to drug discovery, in particular de novo molecule generation and chemical similarity searches. De novo methods generate novel molecules with the decoder portion of a language model after fine-tuning toward a specific molecule or target [14–16, 18]. Building off the recent success of generative models such as GPT, de novo molecule generation has shown promise but is limited due to a lack of generalizability and guaranteed synthesizability [23, 24]. In contrast, a chemical similarity search based on a CLM has the advantage of computational speed, generalizability, and high database control to ensure synthesizability. Sellner et al. recently created a novel transformer-based chemical similarity search with an optimized loss function to approximate previous structure-based methods [12]. However, this method tends to identify molecules with high structural similarity to the query molecule, when instead we would often like to find structurally distinct functional analogues. Such a CLM-based search does not currently exist.

Here, we describe a chemical similarity search based on a CLM that identifies molecules with similar function to a given query molecule. This method works by calculating the CLM-computed feature vector similarity between a query SMILES string and a chemical database. Keeping the SMILES canonicalization algorithm constant between the query and database resulted in a chemical language search that approximated recent transformer-based chemical search methods. However, we found that when the query SMILES string was canonicalized with a different algorithm than was used for the database, the reliance on structural similarity diminished while functional similarity was retained. This behavior seemed reasonable given the literature describing how models learn to better represent chemical space when SMILES randomization occurs during training and from the reported emergent understanding of underrepresented languages in predominantly English-trained models [25–28]. We utilize alternatively canonicalized queries as a novel prompt engineering strategy to identify structurally distinct functional analogues of small molecules. Our method fundamentally differs from existing literature in that SMILES augmentation was used for the query of a chemical similarity search rather than for model training and fine-tuning to a specific task. We tested our method across three canonicalizations and eight query molecules and found that with increasingly divergent canonicalizations we were able to identify structurally distinct functional analogues.

2 Methods

CheSS Overview. The Chemical Semantic Search (CheSS) is a molecular search framework that uses language model-encoded feature vectors to compute similarity scores across molecular space. A database of molecules is encoded as strings using SMILES format [17]. A chemical language model is then used to generate a feature vector for each molecule in the database as well as the query molecule. The cosine similarity between the query vector and each database vector is computed, resulting in a vector of feature cosine similarities.

Language Model. ChemBERTa was used as the language model to generate embeddings [29]. This was a Bidirectional Encoder Representations from Transformers (BERT) model with 12 hidden layers of size 768, and was trained on 10M random non-redundant achiral SMILES strings selected from PubChem [30]. ChemBERTa was chosen over newer, higher-parameter BERT models due to the ease of implementation and publicly available dataset. ChemBERTa does not support isomeric SMILES (chirality), and all SMILES were canonicalized before input.

Database. The CheSS molecular feature database was built from the \sim 10M random achiral molecules used to train ChemBERTa [29]. For each molecule, the SMILES string was canonicalized using RDKit [31]. We reduced this dataset to exclude all SMILES strings that tokenized to more than 512 tokens, the maximum supported by ChemBERTa. This resulted in a database of 9,999,809 molecules. The database SMILES strings were encoded into feature vectors with ChemBERTa. The [CLS] token vector representations of the final layer were chosen to be the feature vectors, as described in the original BERT paper [30]. These feature vectors were then L2 normalized and stored in chunks of 100k SMILES string-feature vector pairs for future cosine similarity calculations.

Canonicalization Query Types. ChemBERTa was trained on SMILES strings canonicalized using RDKit [29, 31]. Different canonicalization algorithms result in different, but equally valid, standardized strings representing the same molecule, which we utilize to create three highly different queries for the same molecule. The first query type used RDKit with its default Python implementation settings. This algorithm was used to canonicalize the database & train the model. When converting molecules to SMILES, RDKit allows specification of which atom number to root the SMILES string to. The default is Atom 0, and each atom results in a different representation. The feature cosine similarity was calculated between the default RDKit SMILES and the "Atom n" RDKit SMILES for each atom in the query molecule, as demonstrated in Figure S2. From these, we took the most dissimilar "Atom n" SMILES strings to be the second query type for each molecule. To obtain a third dissimilar SMILES representation, OEChem 2.3.0, a markedly different canonicalization algorithm than RDKit, was used [32]. These SMILES strings were obtained from the PubChem website.

Similarity Metrics. Various similarity metrics were used throughout, which include feature cosine similarity, Gestalt pattern matching similarity, fingerprint Tanimoto similarity, token vector length similarity, and token similarity [33, 34]. Feature cosine similarity is a distance metric that calculates the angle between two vectors **A** and **B**:

Cosine similarity =
$$\frac{\mathbf{A} \cdot \mathbf{B}}{||\mathbf{A}|| \, ||\mathbf{B}||}$$
. (1)

A cosine similarity of 1 indicates the normalized vectors are the same, 0 means they are orthogonal to one another, and -1 means they are opposite of one another.

Gestalt pattern matching was chosen to calculate string similarity. This metric is calculated by dividing twice the number of matching characters (K_m) by the total number of characters in both strings (S_1, S_2) :

Gestalt similarity =
$$\frac{2K_m}{|S_1| + |S_2|}$$
. (2)

Matching characters are identified first from the longest common substring, with recursive counts in non-matching regions on both sides of the substring. The metric ranges from a perfect match of 1 to a completely dissimilar string of 0. We used the difflib Python implementation of the Gestalt pattern matching algorithm to calculate Gestalt similarity.

Fingerprint Tanimoto similarity was used to calculate the structural similarity between pairs of molecules. This method encodes substructures into a binary vector, and then calculates the Tanimoto similarity between these encoded vectors. The Tanimoto / Jaccard similarity is the number of shared elements (intersection) between two sets A and B over the total number of unique elements in both sets (union) (Eq. 3):

Tanimoto similarity =
$$\frac{A \cap B}{A \cup B}$$
. (3)

This metric ranges from 1 (all elements shared) to 0 (no elements shared). The RDKit default implementation of fingerprint Tanimoto similarity was used herein.

All SMILES were encoded into token vectors before being passed into the model. These tokenized vectors were used for additional comparisons to better understand search behavior. The first metric used from these was the ratio of token lengths between two vectors. The second metric was the token Tanimoto / Jaccard similarity (Eq. 3) between the two molecules' token vectors, and was used to determine the ratio of shared tokens between the two vectors. This metric ranges from 1 (all tokens shared) to 0 (no tokens shared).

Patent & Literature Search. In order to determine known functionality of the molecules examined herein, a patent & literature search was performed. The patents and literature articles for each molecule, if available, was obtained from PubChem [35]. A comprehensive list of all molecules considered herein, & their associated patents, is provided in Table S2.

3 Results and Discussion

In-silico drug discovery methods have long relied on chemical similarity searches as a computational tool in pharmaceutical pipelines [22]. Recently, language models have been successful in biochemical prediction tasks for chemical properties such as drug-likeness, protein-ligand interactions, and other metrics [11, 13]. Because a multitude of characteristics can be predicted from chemical language models (CLMs), it is plausible that embeddings from these models contain a summary of molecular properties for a given molecule. So-called Simplified Molecular Line Entry System (SMILES) representations can be used to represent chemical structures as strings and can be used as inputs to CLMs, but due to the nature of chemical connectivity, there are often many valid representations for the same molecule [17]. This multiplicity of input formats causes the CLM to generate different embeddings for the same molecule, which can either be mitigated through string standardization (canonicalization) or utilized as a data augmentation technique that allows CLMs to better span molecular space [25, 26]. The latter reduces overfitting to string artifacts and improves structural comprehension; an analogy in natural language would be that training a model on all languages improves the understanding of language as a whole compared to a model trained only on English [25, 26].

However, the combination of alternative canonicalizations and data augmentation may actually prove to be advantageous for a chemical similarity search. Recent reports on emergence from the natural language processing literature demonstrated that language models understand Swahili and other languages incredibly well despite them being <0.01% of training data [27, 28]. SMILES canonicalization formats often share characters and substructures with one another, the primary difference being the specific grammatical rules used to assemble a given molecule. For CLMs trained on one canonicalization, inputs using unseen canonicalizations would be akin to underrepresented languages in natural language training sets, as the underlying string structure of the unseen canonicalization is not entirely unknown to the model, but is novel in the context of the molecule at hand. It seems likely that a vector comparison between embeddings from two different canonicalizations could ignore the differences in string and structural data and instead use whole-molecule properties approximating molecular function, serving as a novel prompt engineering strategy for the discovery of structurally distinct functional analogues. This would be equivalent to querying a predominantly English-trained model with a French phrase to obtain an embedding, and then searching amongst English phrases to find the entry with the closest semantic meaning. To our knowledge this potential behavior is largely unexplored.

To test this hypothesis, we built a CLM-embedding-based chemical similarity search utilizing one canonicalization for the CLM and database, and another canonicalization for the query SMILES strings. A pipeline was developed to perform a chemical similarity search using cosine similarity on CLM embeddings obtained from ChemBERTa, an unsupervised transformer encoder-based model [29]. This pipeline was named the Chemical Semantic Search (CheSS), outlined in Figure 1. ChemBERTa was trained on SMILES strings canonicalized using the default RDKit implementation, herein referred to as "RDKit Atom 0" [29, 31]. We converted ChemBERTa's training set into a molecular database of ~10M RDKit Atom 0 SMILES strings, upon which CheSS searches were performed. We then explored how the CheSS search results were impacted by three different SMILES canonicalizations. The first was RDKit's default canonicalization "RDKit Atom 0". The second canonicalization was created by maximizing the distance of the created string embedding to RDKit Atom 0 by varying the root atom number, herein referred to as "RDKit Atom n" (Fig. S2). The third used OEChem 2.3.0, a markedly different algorithm, to canonicalize the query and is referred to as "OEChem". All CheSS searches utilizing these three canonicalizations differed only in the representation of the query molecule, with the database and model remaining constant.



Figure 1: Chemical Semantic Search (CheSS). The query molecule and chemical database are converted into SMILES strings, which are then inputted into a language model to obtain feature vectors. The cosine similarity between the query feature vector and database feature vectors is computed, resulting in a vector of feature cosine similarities.

3.1 Determining Whether Canonicalization Impacts Search Behavior

A CheSS search using each of three, different query canonicalizations was conducted on eight molecules of known function and roughly equal chemical complexity: penicillin G, nirmatrelvir, zidovudine, lysergic acid diethylamide (LSD), fentanyl, acid blue 25 free acid (acid blue 25 FA), avobenzone, and 2-diphenylaminocarbazole (2-dPAC) (Fig. 2). These molecules were chosen as they are of roughly equal complexity but otherwise represent two distinct classes of

molecules: drug-like bioactive molecules and non-drug-like photochemical molecules (herein referred to as dye-like). In addition, the molecules were all sufficiently structurally dissimilar from one another, as determined by having a fingerprint Tanimoto coefficient (Tc) less than 0.60 (Fig S1). That said, acid blue 25 FA was more similar to the drug-like molecules, whereas the dyes avobenzone and 2-dPAC were both highly dissimilar from all other query molecules (Fig. S1).



Figure 2: Query molecules and canonical SMILES representations. Query molecules made achiral during canonicalization. (a). Penicillin G; (b). Nirmatrelvir; (c). Zidovudine; (d). LSD; (e). Fentanyl; (f). Acid blue 25 FA; (g). Avobenzone; (h). 2-dPAC. (i). Penicillin G SMILES strings for the three canonicalizations used herein. Unabridged SMILES for each query are listed in Table S1.

3.1.1 Statistical Analysis of Query Canonicalizations

For each query molecule, several similarity metrics were calculated between the three canonicalizations (pairwise comparisons, Figure 3). Gestalt pattern matching, a string similarity metric, showed that each query canonicalized into different strings, with a mean pairwise value of 0.47 across canonicalizations (n=8) (Fig. 3). Because the CLM does not directly receive strings as inputs, but instead receives the tokenized representations (integer-mapped subsections) of strings, the token vectors were analyzed to understand how these strings would be presented to the model. Tanimoto similarity, a metric comparing shared elements between two sets, was applied to the token vectors which indicated that the query strings were converted using markedly different input tokens (mean pairwise value of 0.69 across canonicalizations) (Fig. 3). Similarly, token vector lengths were variable in length, with some queries differing by almost a factor of 2 depending on canonicalization (Fig. 3). Changes in the token vectors cause differences in featurization, or the model's interpretation of said input, and it was found that different embeddings were obtained depending on canonicalization (mean pairwise feature cosine similarity of 0.66), indicating that the model interpreted different canonicalizations of the same molecule as quite distinct inputs (Fig. 3).

3.1.2 Distribution of Top Hits

In order to explore how different canonicalizations impact feature-based search behavior, similarity metrics were obtained comparing each canonicalized query to its respective top 20 CheSS search results. Queries canonicalized with RDKit Atom 0 yielded compounds high in structural similarity, as evidenced by fingerprint Tanimoto similarity, a measure of molecular substructure similarity, with a mean coefficient of 0.62 (n=160) (Fig. 4d). In contrast, the mean fingerprint Tanimoto coefficients for RDKit Atom n and OEChem were 0.45 and 0.32 respectively. Another way to see the differences in these searches was that for RDKit Atom 0 canonicalized queries, 22% could have been found from a fingerprint Tanimoto search using a cutoff as high as 0.80, indicating that nearly a quarter of the results were 1-2 atomic changes aways from the query molecule (Fig. 4d). In contrast, only 6% and 2% of the top results for RDKit Atom n and OEChem, respectively, could have been found from this same search, indicating significant structural divergence (Fig. 4d).

At a more granular level, these structural differences are well-illustrated for a penicillin G query, in that there is a gradual diminishing of β -lactam-containing results as canonicalization diverges (Figs. 4a, 4b, 4c): all of the top 8 hits for the RDKit Atom 0 canonicalizations contained β -lactams, while progressively fewer lactams were found for RDKit Atom n and OEChem. This trend in diverging structure was partially explained by Gestalt pattern matching similarity, in which the mean scores for RDKit Atom 0, RDKit Atom n, and OEChem were 0.86, 0.65, and 0.44 respectively, indicating that the average RDKit Atom 0 top result was a simple string permutation away from the original query, and thus also a simple structural modification away, but this was not the case for the alternate canonicalizations (Fig. 4d).



Figure 3: Similarity metrics between the three canonicalized representations for each query molecule. Gestalt similarity demonstrates different canonicalizations result in markedly different strings. Token Tanimoto & length ratios indicate these strings were tokenized into different inputs to the CLM. Feature cosine similarity between ChemBERTa-embedded vectors demonstrate that the differently canonicalized queries' token vectors were interpreted differently by the model resulting in increased spread across feature space. Deviations from 1.0 for each metric represent divergence between canonicalizations.

The token vector Tanimoto similarity demonstrated that RDKit Atom 0 canonicalization returned molecules with a high number of shared tokens to the query (mean of 0.80), whereas this was not the case with RDKit Atom n and OEChem (means 0.65, 0.60), indicating that the model's ability to memorize tokens to determine feature similarity was reduced by different canonicalizations (Fig. 4d). These results point to the possibility that the model utilizes non-obvious relationships to determine the alternative canonicalization's location in feature space.

Interestingly, it was observed that the token vector length ratios for all canonicalizations' results fell within about 20% of each query's token vector length, indicating that the model heavily utilized token vector length to determine feature space location and thus similarity (Fig. 4d). This means that token vector length may constrain CLM-based similarity searches to confined regions of chemical space, with alternative canonicalizations acting as ways to bypass this predominant search criteria and thereby explore more distant regions of chemical space through variations in token vector length, ultimately allowing for more comprehensive and far-reaching similarity searches (Figs. 4e, 4f).

3.1.3 Patent Search Reveals Functionality of Molecules

In order to begin to determine the functional significance of the search results, patent and literature searches were conducted on the top 20 results from each search. In general, functionally drug-like queries returned high levels of drug-like molecules and few dye-like molecules, and conversely, queries on functionally dye-like molecules returned more dye-like molecules, and many fewer drug-like molecules (Figs. 5a, 5b). An exception to the latter statement were molecules identified using OEChem inquiries, but this skew was due almost solely to results from the avobenzone search (which in turn has known biological activity [46, 47]). In general, the baseline of random drug-like molecules returned for drug-based queries exists, but is relatively low.

The functional similarity of query results was contrasted with fingerprint Tanimoto similarity (Fig. 5c). The categorization of functionality was either positive (known relevant functionality to the query) or negative (unknown relevant functionality), and the structural similarity was either positive ($Tc \ge 0.60$) or negative (Tc < 0.60). Criteria / ontologies for similar functionality for each molecule were as follows: Penicillin G: antibiotic [3]; nirmatrelvir: protease inhibitor or antiviral [36]; zidovudine: antiviral [37]; LSD: 5-HT receptor agonist or dopaminergic agonist [38, 39]; fentanyl:



Figure 4: Search behavior depends on canonicalization. (a-c). Different canonicalizations return structurally distinct molecules, demonstrated by β -lactam ring-containing molecules in the top search results. (a). RDKit Atom 0 had 8/8 top results containing β -lactam rings. (b). RDKit Atom n had 7/8 top results containing β -lactam rings. (c). OEChem had 3/8 top results containing β -lactam rings. (d). Similarity metrics for all CheSS searches between each canonicalized query and respective top 20 results (n=160 for each canonicalization). Asterisks indicate the level of statistical significance for two-sided independent t-tests (ns, P<1.0; *, P<0.05; **, P<0.01; ***, P<0.001; **** P<0.0001). (e-f). The index rank of each alternate canonicalization's top 20 results for penicillin G compared to the index rank that these same molecules scored in the other canonicalizations' searches. Molecules functionally similar to the query indicated by a black dot, as determined by the patent search, and structurally similar to the query (Tc ≥ 0.60) indicated by a dashed line. Rank plots for each query and comparisons between RDKit Atom n and OEChem are listed in Fig. S7. Queries with alternative canonicalizations were able to find molecules that would not have been found when the same canonicalization as the database was used, which were often functionally similar to the query.

opioid analgesic or muscarinic receptor agonist [40–42]; acid blue 25 FA: dye or electroluminescent; avobenzone: UV-Absorption, electroluminescent [43, 44]; 2-dPAC: electroluminescent [45]. To illustrate, for OEChem-canonicalized nirmatrelvir (a SARS-CoV-2 main protease inhibitor) several top results (7, 8, 16, and 17) were classified as positive, as these compounds were known protease inhibitors and / or antivirals (Figs. 6h 6i, 6j). A table of the top 20 results for each search, complete with links to their PubChem pages, relevant patents and functional descriptors is listed in Table S2.



Figure 5: Patent-derived functional analysis for each canonicalization's results. (a). Mean drug-like & dye-like molecules returned in the top 20 results from drug-like queries (95% CI, n=8). (b). Mean drug-like & dye-like molecules returned in the top 20 results from drug-like queries (95% CI, n=8). (c). Structure-function categorization across all queries for each canonicalization (n=8 for each canonicalization). Structural similarity determined by fingerprint Tanimoto similarity (+ indicates $Tc \ge 0.60$, and – indicates Tc < 0.60). Functional similarity determined by patent search (+ indicates similar function, – indicates no known relevant function to query). Criteria for similar function for each molecule was as follows: Penicillin G: antibiotic [3]; nirmatrelvir: protease inhibitor or antiviral [36]; zidovudine: antiviral [37]; LSD: 5-HT receptor agonist or dopaminergic agonist [38, 39]; fentanyl: opioid analgesic or muscarinic receptor agonist [40–42]; acid blue 25 FA: dye or electroluminescent; avobenzone: UV-Absorption, electroluminescent [43, 44]; 2-dPAC: electroluminescent [45]. (d). Mean non-derivative functional analogues returned in the top 20 results (95% CI, n=8). Asterisks indicate the level of statistical significance for two-sided independent t-tests (ns, P<1.0; *, P<0.05; **, P<0.01; ***, P<0.001; **** P<0.0001).

As expected, CheSS searches with the query molecules canonicalized with RDKit Atom 0 resulted in the identification of molecules with similar structures and functions. There were 31 structurally dissimilar molecules (Tc < 0.60) with shared functionality to the query, 30 of which were nonetheless obvious structural derivatives. Penicillin G returned β -lactam antibiotics, nirmatrelvir returned Hepatitis C Virus (HCV) protease inhibitors, zidovudine returned antiviral pyrimidine nucleosides, LSD returned psychoactive ergolines, fentanyl returned narcotic piperidine analogues, acid blue 25 FA returned anthraquinone dyes, avobenzone returned dibenzoylmethane permutants, and 2-dPAC returned electroluminescent carbazole and triphenylamine derivatives.

In contrast to RDKit Atom 0 queries, RDKit Atom n queries returned molecules that had greater structural diversity, but that still contained many structural analogues. There were 26 structurally dissimilar molecules (Tc < 0.60) with



Figure 6: Structures of molecules discussed herein. (a). RDKit Atom n zidovudine top result #2; **(b).** RDKit Atom n LSD top result #7; **(c).** RDKit Atom n acid blue 25 FA top result #9; **(d).** RDKit Atom n avobenzone top result #13; **(e).** RDKit Atom n fentanyl top result #20; **(f).** RDKit Atom n penicillin G top result #9; **(g).** OEChem nirmatrelvir top result #16; **(h).** OEChem nirmatrelvir top result #17; **(i).** OEChem nirmatrelvir top result #8; **(j).** OEChem LSD top result #14; **(l).** OEChem acid blue 25 FA top result #5; **(m).** OEChem acid blue 25 FA top result #20; **(n).** OEChem 2-dPAC top result #15.

shared functionality to the query, some 22 of which were relatively obvious structural derivatives, including purine and pyrimidine analogs of zidovudine (Fig. 6a). However, these hits also included a quite distinct dopaminergic agonist for LSD (Fig. 6b), a hydrophobic fluorescence probe for acid blue 25 FA (Fig. 6c), a refractive copolymer for avobenzone (Fig. 6d), and a fentanyl-like agonist for its known coronary muscarinic receptor (Fig. 6e) [41, 42]. 2-dPAC did not return any molecules with known relevant functionality using this canonicalization, though the results had similar aromaticity to the query. Interestingly, tetracycline antibiotics have been used to inhibit metalloproteases, and the penicillin G query returned two non-tetracycline metalloprotease inhibitors (Fig. 6f) [48].

OEChem generally returned molecules that were structurally highly dissimilar to the query. There were 35 structurally dissimilar molecules (Tc < 0.60) with shared functionality to the query, and in contrast to the previous two canonicalizations, only 7 of these were obvious structural derivatives. The more diverse compounds with shared functionality included two non-HCV protease inhibitors (Figs. 6g, 6h); a Respiratory Syncytial Virus antiviral for nirmatrelvir (Fig. 6i); a dopaminergic and serotonergic agonist (Fig. 6j) and a 5-HT1 receptor agonist for LSD (Fig. 6k); porphyrins (Fig. 6l) and other conjugated dyes for acid blue 25 FA (Fig. 6m); photovoltaic and electroluminescent molecules for avobenzone; and highly conjugated electroluminescent molecules for 2-dPAC (Fig. 6n). Taken together, these hits provide anecdotal proof for the hypothesis that changing query canonicalizations can lead to the discovery of novel, but functional, chemical compounds. These insights may provide interesting avenues for drug repurposing, and that molecules with previously unknown functions may serve as leads for novel drug discovery.

3.2 Explanation of Search Behavior

We find that alternative canonicalizations influence the search behavior of CheSS through changes in tokenization, which causes the CLM to weight higher-order relationships more importantly when creating embeddings. There are stark differences between RDKit and OEChem canonicalizations, notably their differences in the representation of aromatic rings. OEChem prefers the Kekulé form (C1=CC=CC=C1), while RDKit prefers to use lowercase with assumed aromaticity (c1cccc1), and these differences, among others, result in markedly different tokenization, both in the composition and the length of the tokenized vectors (Fig. 4). Since the CLM has demonstrated a bias toward embedding molecules with similar token vector lengths and (to a lesser extent) token composition to the query (Fig. 4), a query with a different canonicalization will tokenize into a radically different token vector and thereby make the CLM more likely to return molecules with SMILES representations that are highly dissimilar from the original same-canonicalized query. Despite this behavior, and potentially because of it, CheSS searches with alternative canonicalizations found diverse chemical structures with similar functional properties, as demonstrated by patent and literature searches (Fig. 5).

When CLMs are forced to go beyond simple token patterns to determine similarity, more nuanced relationships may appear. Given the nature of transformers, it is indiscernible what these relationships are, but based on our analysis we find it possible that the CLM may, for example, key on the apposition of functional groups in space, in a way similar to how receptors perceive ligands.

3.3 Drawbacks, Future Improvements, and Potential for Misuse

The database used by CheSS consisted of the $\sim 10M$ molecules used as a training set for ChemBERTa, and thus it is difficult to predict the behavior of queries that differ greatly from the molecules in this dataset. In addition, very small molecules may not differ in their canonicalized representations, leading to more homogeneity between queries. Nonetheless, the method itself is extensible for use with any dataset, and may invite discussions regarding what datasets and CLMs are most useful for moving between different canonicalizations to identify functional analogues. We did not at this time explore whether non-canonicalized, yet valid, variations of SMILES strings will lead to similar results.

We also note that the threat of dual use for chemical machine learning models has been a topic of discussion amongst researchers [49]. While the model used in our implementation of CheSS was unsupervised and not trained for identifying toxic molecules, a successful chemical similarity search tool carries inherent risks. We therefore advise caution in considering public implementations of these tools and recommend restricting searches to avoid queries with the potential for malicious use.

4 Conclusion

In this study, we created a chemical similarity search pipeline utilizing a transformer encoder-based chemical language model to generate embeddings upon which similarity scores can be computed. From this, we designed a prompt engineering strategy that expands upon existing chemical semantic searches by creating a method able to identify structurally dissimilar molecules with similar function. We demonstrate the utility of this search method to identify non-obvious functional compounds related to multiple different query molecules. This method may aid repurposing known compounds or in discovering new structural classes of molecules that have desirable functionality. Despite potential drawbacks, we believe that CheSS and the canonicalization prompt engineering method discussed herein will be of broad interest to the chemical community, as it begins to explore how machine learning can be used outside of staid similarity queries.

5 Acknowledgements

The authors acknowledge the Texas Advanced Computing Center at The University of Texas at Austin for providing high-performance computing resources. This work was supported by the Welch Foundation (C.W.K.), the Blumberg Centennial Professorship in Molecular Evolution (C.O.W.), and the Reeder Centennial Fellowship in Systematic and Evolutionary Biology at The University of Texas at Austin (C.O.W.).

6 Author Contributions

Conceptualization, C.W.K. and A.L.F.; Methodology, C.W.K.; Software, C.W.K. and A.L.F.; Validation, C.W.K. and A.L.F; Formal Analysis, C.W.K.; Investigation, C.W.K.; Resources, A.D.E., C.O.W.; Data Curation, C.W.K. and A.L.F.; Writing - Original Draft, C.W.K. and A.L.F.; Writing - Review & Editing, C.W.K., A.L.F., A.D.E., and C.O.W.; Visualization, C.W.K and A.L.F.; Supervision, A.D.E. and C.O.W.; Funding Acquisition, A.D.E. and C.O.W.

7 Declaration of Interests

The authors declare no competing interests.

8 Data and Code Availability

Project code and discussed search results can be found at https://github.com/kosonocky/CheSS.

References

- [1] Qingxin Li and CongBao Kang. Mechanisms of action for small molecules revealed by structural biology in drug discovery. *International Journal of Molecular Sciences*, 21(15):5262, 2020.
- [2] Gordon M Cragg and David J Newman. Biodiversity: A continuing source of novel drug leads. *Pure and applied chemistry*, 77(1):7–24, 2005.
- [3] Alexander Fleming. Penicillin. *British medical journal*, 2(4210):386, 1941.

- [4] Rui H Jiao, Shu Xu, Jun Y Liu, Hui M Ge, Hui Ding, Chen Xu, Hai L Zhu, and Ren X Tan. Chaetominine, a cytotoxic alkaloid produced by endophytic chaetomium sp. ifb-e015. Organic Letters, 8(25):5709–5712, 2006.
- [5] Mansukh C Wani and Susan Band Horwitz. Nature as a remarkable chemist: A personal story of the discovery and development of taxol[®]. *Anti-cancer drugs*, 25(5):482, 2014.
- [6] James P Hughes, Stephen Rees, S Barrett Kalindjian, and Karen L Philpott. Principles of early drug discovery. *British journal of pharmacology*, 162(6):1239–1249, 2011.
- [7] Yvonne C Martin, James L Kofron, and Linda M Traphagen. Do structurally similar molecules have similar biological activity? *Journal of medicinal chemistry*, 45(19):4350–4358, 2002.
- [8] Hasan Pathan and John Williams. Basic opioid pharmacology: an update. *British journal of pain*, 6(1):11–16, 2012.
- [9] Limeng Pu, Misagh Naderi, Tairan Liu, Hsiao-Chun Wu, Supratik Mukhopadhyay, and Michal Brylinski. etoxpred: a machine learning-based approach to estimate the toxicity of drug candidates. *BMC Pharmacology and Toxicology*, 20(1):1–15, 2019.
- [10] Yilin Yang, Mingjie Liu, and John R Kitchin. Neural network embeddings based similarity search method for atomistic systems. *Digital Discovery*, 1(5):636–644, 2022.
- [11] Kyunghoon Lee, Jinho Jang, Seonghwan Seo, Jaechang Lim, and Woo Youn Kim. Drug-likeness scoring based on unsupervised learning. *Chemical Science*, 13(2):554–565, 2022.
- [12] Manuel S Sellner, Amr H Mahmoud, and Markus A Lill. Efficient virtual high-content screening using a distance-aware transformer model. *Journal of Cheminformatics*, 15(1):18, 2023.
- [13] Bomin Wei, Yue Zhang, and Xiang Gong. Deeplpi: a novel deep learning-based model for protein–ligand interaction prediction for drug repurposing. *Scientific reports*, 12(1):18200, 2022.
- [14] Michael Moret, Francesca Grisoni, Paul Katzberger, and Gisbert Schneider. Perplexity-based molecule ranking and bias estimation of chemical language models. *Journal of chemical information and modeling*, 62(5):1199–1206, 2022.
- [15] Michael Moret, Irene Pachon Angona, Leandro Cotos, Shen Yan, Kenneth Atz, Cyrill Brunner, Martin Baumgartner, Francesca Grisoni, and Gisbert Schneider. Leveraging molecular structure and bioactivity with chemical language models for de novo drug design. *Nature Communications*, 14(1):114, 2023.
- [16] Daniel Flam-Shepherd, Kevin Zhu, and Alán Aspuru-Guzik. Language models can learn complex molecular distributions. *Nature Communications*, 13(1):3293, 2022.
- [17] David Weininger. Smiles, a chemical language and information system. 1. introduction to methodology and encoding rules. *Journal of chemical information and computer sciences*, 28(1):31–36, 1988.
- [18] Jerret Ross, Brian Belgodere, Vijil Chenthamarakshan, Inkit Padhi, Youssef Mroueh, and Payel Das. Large-scale chemical language representations capture molecular structure and properties. *Nature Machine Intelligence*, 4(12): 1256–1264, 2022.
- [19] Benjamin I Tingle, Khanh G Tang, Mar Castanon, John J Gutierrez, Munkhzul Khurelbaatar, Chinzorig Dandarchuluun, Yurii S Moroz, and John J Irwin. Zinc-22- a free multi-billion-scale database of tangible compounds for ligand discovery. *Journal of Chemical Information and Modeling*, 63(4):1166–1176, 2023.
- [20] Maria Batool, Bilal Ahmad, and Sangdun Choi. A structure-based drug discovery paradigm. *International journal of molecular sciences*, 20(11):2783, 2019.
- [21] Katalin Szilágyi, Beáta Flachner, István Hajdú, Mária Szaszkó, Krisztina Dobi, Zsolt Lőrincz, Sándor Cseh, and György Dormán. Rapid identification of potential drug candidates from multi-million compounds' repositories. combination of 2d similarity search with 3d ligand/structure based methods and in vitro screening. *Molecules*, 26 (18):5593, 2021.
- [22] Dagmar Stumpfe and Jürgen Bajorath. Similarity searching. Wiley Interdisciplinary Reviews: Computational Molecular Science, 1(2):260–282, 2011.
- [23] Tom Brown, Benjamin Mann, Nick Ryder, Melanie Subbiah, Jared D Kaplan, Prafulla Dhariwal, Arvind Neelakantan, Pranav Shyam, Girish Sastry, Amanda Askell, et al. Language models are few-shot learners. Advances in neural information processing systems, 33:1877–1901, 2020.
- [24] Wenhao Gao and Connor W Coley. The synthesizability of molecules proposed by generative models. *Journal of chemical information and modeling*, 60(12):5714–5723, 2020.

- [25] Josep Arús-Pous, Simon Viet Johansson, Oleksii Prykhodko, Esben Jannik Bjerrum, Christian Tyrchan, Jean-Louis Reymond, Hongming Chen, and Ola Engkvist. Randomized smiles strings improve the quality of molecular generative models. *Journal of cheminformatics*, 11(1):1–13, 2019.
- [26] Maranga Mokaya, Fergus Imrie, Willem P van Hoorn, Aleksandra Kalisz, Anthony R Bradley, and Charlotte M Deane. Testing the limits of smiles-based de novo molecular generation with curriculum and deep reinforcement learning. *Nature Machine Intelligence*, pages 1–9, 2023.
- [27] Jason Wei, Yi Tay, Rishi Bommasani, Colin Raffel, Barret Zoph, Sebastian Borgeaud, Dani Yogatama, Maarten Bosma, Denny Zhou, Donald Metzler, et al. Emergent abilities of large language models. arXiv preprint arXiv:2206.07682, 2022.
- [28] Freda Shi, Mirac Suzgun, Markus Freitag, Xuezhi Wang, Suraj Srivats, Soroush Vosoughi, Hyung Won Chung, Yi Tay, Sebastian Ruder, Denny Zhou, et al. Language models are multilingual chain-of-thought reasoners. arXiv preprint arXiv:2210.03057, 2022.
- [29] Seyone Chithrananda, Gabriel Grand, and Bharath Ramsundar. Chemberta: Large-scale self-supervised pretraining for molecular property prediction. CoRR, abs/2010.09885, 2020. URL https://arxiv.org/abs/2010.09885.
- [30] Jacob Devlin, Ming-Wei Chang, Kenton Lee, and Kristina Toutanova. BERT: pre-training of deep bidirectional transformers for language understanding. *CoRR*, abs/1810.04805, 2018. URL http://arxiv.org/abs/1810. 04805.
- [31] Greg Landrum et al. Rdkit: A software suite for cheminformatics, computational chemistry, and predictive modeling. *Greg Landrum*, 8, 2013.
- [32] TK OEChem. version 2.3.0; openeye scientific software: Santa fe, nm.
- [33] John W Ratcliff and David E Metzener. Pattern-matching-the gestalt approach. Dr Dobbs Journal, 13(7):46, 1988.
- [34] Dávid Bajusz, Anita Rácz, and Károly Héberger. Why is tanimoto index an appropriate choice for fingerprint-based similarity calculations? *Journal of cheminformatics*, 7(1):1–13, 2015.
- [35] Sunghwan Kim, Paul A Thiessen, Evan E Bolton, Jie Chen, Gang Fu, Asta Gindulyte, Lianyi Han, Jane He, Siqian He, Benjamin A Shoemaker, et al. Pubchem substance and compound databases. *Nucleic acids research*, 44(D1): D1202–D1213, 2016.
- [36] Jennifer Hammond, Heidi Leister-Tebbe, Annie Gardner, Paula Abreu, Weihang Bao, Wayne Wisemandle, MaryLynn Baniecki, Victoria M Hendrick, Bharat Damle, Abraham Simón-Campos, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19. *New England Journal of Medicine*, 386(15):1397–1408, 2022.
- [37] Margaret A Fischl, Douglas D Richman, Nellie Hansen, Ann C Collier, John T Carey, Michael F Para, W David Hardy, Raphael Dolin, William G Powderly, J Davis Allan, et al. The safety and efficacy of zidovudine (azt) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (hiv) infection: a double-blind, placebo-controlled trial. *Annals of internal medicine*, 112(10):727–737, 1990.
- [38] M Titeler, RA Lyon, and RA Glennon. Radioligand binding evidence implicates the brain 5-ht 2 receptor as a site of action for lsd and phenylisopropylamine hallucinogens. *Psychopharmacology*, 94:213–216, 1988.
- [39] Lorenzo Pieri, Margherita Pieri, and Willy Haefely. Lsd as an agonist of dopamine receptors in the striatum. *Nature*, 252:586–588, 1974.
- [40] Patil Armenian, Kathy T Vo, Jill Barr-Walker, and Kara L Lynch. Fentanyl, fentanyl analogs and novel synthetic opioids: a comprehensive review. *Neuropharmacology*, 134:121–132, 2018.
- [41] Takao Yamanoue, Jose M Brum, Fawzy G Estafanous, Philip A Khairallah, and Carlos M Ferrario. Fentanyl attenuates porcine coronary arterial contraction through m3-muscarinic antagonism. *Anesthesia & Analgesia*, 76 (2):382–390, 1993.
- [42] Olav Hustveit. Binding of fentanyl and pethidine to muscarinic receptors in rat brain. *The Japanese Journal of Pharmacology*, 64(1):57–59, 1994.
- [43] S Afonso, K Horita, JP Sousa e Silva, IF Almeida, MH Amaral, PA Lobão, PC Costa, Margarida S Miranda, Joaquim CG Esteves da Silva, and JM Sousa Lobo. Photodegradation of avobenzone: Stabilization effect of antioxidants. *Journal of Photochemistry and Photobiology B: Biology*, 140:36–40, 2014.
- [44] Yuyang Zhou, Jinyong Zhuang, Wenming Su, and Xiaomei Wang. Yellow organic light-emitting diodes from heteroleptic iridium (iii) complexes with avobenzone ligands as dopants. *European Journal of Inorganic Chemistry*, 2015(33):5571–5576, 2015.
- [45] A Venkateswararao, KR Justin Thomas, Chuan-Pei Lee, and Kuo-Chuan Ho. Effect of auxiliary chromophores on the optical, electrochemical, and photovoltaic properties of carbazole-based dyes. *Asian Journal of Organic Chemistry*, 4(1):69–80, 2015.

- [46] Sungjin Ahn, Seungchan An, Moonyoung Lee, Eunyoung Lee, Jeong Joo Pyo, Jeong Hyeon Kim, Min Won Ki, Sun Hee Jin, Jaehyoun Ha, and Minsoo Noh. A long-wave uva filter avobenzone induces obesogenic phenotypes in normal human epidermal keratinocytes and mesenchymal stem cells. *Archives of toxicology*, 93:1903–1915, 2019.
- [47] Changwon Yang, Whasun Lim, Fuller W Bazer, and Gwonhwa Song. Avobenzone suppresses proliferative activity of human trophoblast cells and induces apoptosis mediated by mitochondrial disruption. *Reproductive Toxicology*, 81:50–57, 2018.
- [48] Michele M Castro, Arulmozhi D Kandasamy, Nermeen Youssef, and Richard Schulz. Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases. *Pharmacological Research*, 64(6):551–560, 2011.
- [49] Fabio Urbina, Filippa Lentzos, Cédric Invernizzi, and Sean Ekins. Dual use of artificial-intelligence-powered drug discovery. *Nature Machine Intelligence*, 4(3):189–191, 2022.

Supplementary Figures

Table S1:	Table S1: Different canonical SMILES string representations for each molecule query molecule.											
Query	Canon Alg.	SMILES										
	RDKit Atom 0	CC1(C)SC2C(NC(=O)Cc3ccccc3)C(=O)N2C1C(=O)[O-]										
Penicillin G	RDKit Atom 13	c1ccc(CC(=O)NC2C(=O)N3C2SC(C)(C)C3C(=O)[O-])cc1										
	OEChem	CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=C3)C(=O)[O-])C										
	RDKit Atom 0	CC(C)(C)C(NC(=O)C(F)(F)F)C(=O)N1CC2C(C1C(=O)NC(C#N)CC1CCNC1=O)C2(C)C										
Nirmatrelvir	RDKit Atom 21	N(C(=O)C1C2C(CN1C(=O)C(NC(=O)C(F)(F)F)C(C)(C)C)C2(C)C)C(C#N)CC1CCNC1=O										
	OEChem	CC1(C2C1C(N(C2)C(=O)C(C(C)(C)C)NC(=O)C(F)(F)F)C(=O)NC(CC3CCNC3=O)C#N)C										
	RDKit Atom 0	Cc1cn(C2CC(N=[N+]=[N-])C(CO)O2)c(=O)[nH]c1=O										
Zidovudine	RDKit Atom 15	O=c1[nH]c(=O)c(C)cn1C1CC(N=[N+]=[N-])C(CO)O1										
	OEChem	CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)N=[N+]=[N-]										
	RDKit Atom 0	CCN(CC)C(=O)C1C=C2c3cccc4[nH]cc(c34)CC2[NH+](C)C1										
LSD	RDKit Atom 9	C12=CC(C(=O)N(CC)CC)C[NH+](C)C1Cc1c[nH]c3cccc2c13										
	OEChem	CCN(CC)C(=0)C1C[NH+](C2CC3=CNC4=CC=CC(=C34)C2=C1)C										
	RDKit Atom 0	CCC(=O)N(c1ccccc1)C1CC[NH+](CCc2cccc2)CC1										
Fentanyl	RDKit Atom 17	c1(CC[NH+]2CCC(N(C(=O)CC)c3ccccc3)CC2)ccccc1										
	OEChem	CCC(=0)N(C1CC[NH+](CC1)CCC2=CC=C2)C3=CC=C2										
	RDKit Atom 0	Nc1c(S(=O)(=O)[O-])cc(Nc2cccc2)c2c1C(=O)c1ccccc1C2=O										
Acid Blue 25 FA	RDKit Atom 26	C1(=O)c2cccc2C(=O)c2c(N)c(S(=O)(=O)[O-])cc(Nc3cccc3)c21										
	OEChem	C1=CC=C(C=C1)NC2=CC(=C(C3=C2C(=O)C4=CC=CC=C4C3=O)N)S(=O)(=O)[O-]										
	RDKit Atom 0	COc1ccc(C(=O)CC(=O)c2ccc(C(C)(C)C)cc2)cc1										
Avobenzone	RDKit Atom 8	C(C(=O)c1ccc(OC)cc1)C(=O)c1ccc(C(C)(C)C)cc1										
	OEChem	CC(C)(C)C1=CC=C(C=C1)C(=O)CC(=O)C2=CC=C(C=C2)OC										
	RDKit Atom 0	c1ccc(N(c2cccc2)c2ccc3c(c2)[nH]c2cccc23)cc1										
2-dPAC	RDKit Atom 18	c12ccccc1c1ccc(N(c3ccccc3)c3ccccc3)cc1[nH]2										
	OEChem	C1=CC=C(C=C1)N(C2=CC=C2)C3=CC4=C(C=C3)C5=CC=C5N4										

Table S1: Different canonical SMILES string representations for each molecule query molecule.

		G	wit	^o			258	r de		
	Penici	lin Airm	atron Lidow	uditt LSD	Fentre	Acid F	Avobe Avobe	entor dep	Ç	- 1 0
Penicillin G	1	0.38	0.33	0.39	0.28	0.34	0.17	0.16		- 1.0
Nirmatrelvir	0.38	1	0.28	0.33	0.25	0.28	0.13	0.15		- 0.8 dit
Zidovudine	0.33	0.28	1	0.38	0.2	0.32	0.14	0.16		Similar
LSD	0.39	0.33	0.38	1	0.28	0.38	0.19	0.21		moto 6.0 -
Fentanyl	0.28	0.25	0.2	0.28	1	0.23	0.18	0.16		nt Tani
Acid Blue 25 FA	0.34	0.28	0.32	0.38	0.23	1	0.16	0.2		gerpri
Avobenzone	0.17	0.13	0.14	0.19	0.18	0.16	1	0.11		- 0.2 ^변
2-dPAC	0.16	0.15	0.16	0.21	0.16	0.2	0.11	1		- 0.0

Figure S1: Fingerprint Tanimoto coefficients between each of the query molecules. The drug-like molecules, as well as acid blue 25 FA, are more similar to one another than they are to avobenzone & 2-dPAC. All of the molecules are fairly dissimilar to one another, with the highest similarity being 0.39 between LSD and penicillin G, and the lowest similarity being 0.11 between avobenzone and 2-dPAC.



Figure S2: Feature cosine similarity of each RDKit canonicalized query depending on the chosen root atom number. (a-h). In order: penicillin G, nirmatrelvir, zidovudine, LSD, fentanyl, acid blue 25 FA, avobenzone, 2-dPAC. The canonicalized variant with the lowest feature similarity to the Atom 0 representation was chosen as the "RDKit Atom n query". The root atoms providing most dissimilar feature vectors to the Atom 0 representations were 13 for penicillin G, 21 for nirmatrelvir, 15 for zidovudine, 9 for LSD, 17 for fentanyl, 26 for acid blue 25 FA, 8 for avobenzone, and 18 for 2-dPAC.



Figure S3: Fingerprint Tanimoto coefficients between the query molecule and the top 20 most similar molecules to the query (by feature cosine similarity) for each canonicalization. (a-c). In order: RDKit Atom 0, RDKit Atom n, OEChem. These demonstrate that the RDKit Atom 0 search is providing results similar to a fingerprint structural search, whereas this is less so the case in RDKit Atom n, and even less so in the OEChem search. The exception to this is 2-dPAC, in which none of the molecules would have reasonably been found with a fingerprint search.



(c)

Figure S4: Gestalt similarity between the strings of the top 20 most similar molecules to the query (by feature cosine similarity) and the canonicalized query string of each respective canonicalization. (a-c). In order: RDKit Atom 0, RDKit Atom n, OEChem. These demonstrate that the RDKit Atom 0 search is providing results very similar to a simple string similarity search, whereas this is less so the case in RDKit Atom n, and even less so in the OEChem search.



Figure S5: Token vector Tanimoto ratios between the query molecule's tokenized SMILES vector and the tokenized SMILES vectors of the top 20 most similar molecules to the query (by feature cosine similarity) for each canonicalization. (a-c). In order: RDKit Atom 0, RDKit Atom n, OEChem. These demonstrate that searches using RDKit Atom 0 to canonicalize the SMILES string will return molecules with a high number of shared tokens to the query, whereas this is less so the case with RDKit Atom n and OEChem. Despite these differences, nearly all of the top results share at least 50% of the tokens with the query.



(c)

Figure S6: Token vector length ratio between the query molecule's tokenized SMILES vector and the tokenized SMILES vectors of the top 20 most similar molecules to the query (by feature cosine similarity) for each canonicalization. These demonstrate that the length of the tokenized vectors for almost all of the results fall within 20% of the query's length, indicating that the length of the tokenized SMILES vector is a significant factor in how the top results are determined.



Figure S7: The index rank of each alternate canonicalization's top 20 results for each query compared to the index rank that these same molecules scored in the other canonicalizations' searches. (a-h). In order: penicillin G, nirmatrelvir, zidovudine, LSD, fentanyl, acid blue 25 FA, avobenzone, 2-dPAC. Molecules functionally similar to the query indicated by a black dot, as determined by the patent search, and structurally similar to the query ($Tc \ge 0.60$) indicated by a dashed line. These demonstrate that queries that underwent alternative canonicalization were able to identify functional molecules that would have been impractical to find using the standard canonicalization.



Figure S7: The index rank of each alternate canonicalization's top 20 results for each query compared to the index rank that these same molecules scored in the other canonicalizations' searches. (a-h). In order: penicillin G, nirmatrelvir, zidovudine, LSD, fentanyl, acid blue 25 FA, avobenzone, 2-dPAC. Molecules functionally similar to the query indicated by a black dot, as determined by the patent search, and structurally similar to the query ($Tc \ge 0.60$) indicated by a dashed line. These demonstrate that queries that underwent alternative canonicalization were able to identify functional molecules that would have been impractical to find using the standard canonicalization.



Figure S7: The index rank of each alternate canonicalization's top 20 results for each query compared to the index rank that these same molecules scored in the other canonicalizations' searches. (a-h). In order: penicillin G, nirmatrelvir, zidovudine, LSD, fentanyl, acid blue 25 FA, avobenzone, 2-dPAC. Molecules functionally similar to the query indicated by a black dot, as determined by the patent search, and structurally similar to the query ($Tc \ge 0.60$) indicated by a dashed line. These demonstrate that queries that underwent alternative canonicalization were able to identify functional molecules that would have been impractical to find using the standard canonicalization.



Figure S7: The index rank of each alternate canonicalization's top 20 results for each query compared to the index rank that these same molecules scored in the other canonicalizations' searches. (a-h). In order: penicillin G, nirmatrelvir, zidovudine, LSD, fentanyl, acid blue 25 FA, avobenzone, 2-dPAC. Molecules functionally similar to the query indicated by a black dot, as determined by the patent search, and structurally similar to the query ($Tc \ge 0.60$) indicated by a dashed line. These demonstrate that queries that underwent alternative canonicalization were able to identify functional molecules that would have been impractical to find using the standard canonicalization.





(**t**) LSD RDKit Atom 0 (11-20)



(ad) Fentanyl OEChem (11-20)



(an) Avobenzone RDKit Atom n (11-20)



Query	Canon.	Rank	CID	Patent ID / DOI	Functional Descriptor	Drug	Dye	Sim. Fun.	Тс	SDFA	NDFA
Pen.	RDKit 0	1	18643908	US-4996313-A	Beta-Lactam Antibiotic	1	0	1	0.78	0	0
Pen.	RDKit 0	2	70630416	US-4171304-A	Beta-Lactam Antibiotic	1	0	1	0.92	0	0
Pen.	RDKit 0	3	23616098	n/a	n/a	0	0	0	0.72	0	0
Pen.	RDKit 0	4	70367018	n/a	n/a	0	0	0	0.92	0	0
Pen.	RDKit 0	5	21500059	US-4010156-A	Beta-Lactam Antibiotic	1	0	1	0.75	0	0
Pen.	RDKit 0	6	57624296	US-2009081766-A1	Beta-Lactam Antibiotic	1	0	1	0.49	1	0
Pen.	RDKit 0	7	58112358	US20190315770A1	Beta-Lactam Antibiotic	1	0	1	0.7	0	0
Pen.	RDKit 0	8	20389584	US-4171304-A	Beta-Lactam Antibiotic	1	0	1	0.83	0	0
Pen.	RDKit 0	9	56988098	US-4461726-A	Beta-Lactam Antibiotic	1	0	1	0.68	0	0
Pen.	RDKit 0	10	102119253	n/a	n/a	0	0	0	0.71	0	0
Pen.	RDKit 0	11	13277548	US-4942229-A	Beta-Lactam Antibiotic	1	0	1	0.94	0	0
Pen.	RDKit 0	12	152766084	US-3954732-A	Beta-Lactam Antibiotic	1	0	1	0.69	0	0
Pen.	RDKit 0	13	22874634	US-5656623-A	Beta-Lactam Antibiotic	1	0	1	0.83	0	0
Pen.	RDKit 0	14	4393031	n/a	n/a	0	0	0	0.81	0	0
Pen.	RDKit 0	15	56628131	US-4847247-A	Elastase Inhibitor	1	0	0	0.9	0	0
Pen.	RDKit 0	16	11741115	n/a	n/a	0	0	0	0.8	0	0
Pen.	RDKit 0	17	54281720	US4077967A	Beta-Lactam Antibiotic	1	0	1	0.96	0	0
Pen.	RDKit 0	18	70547535	EP-0005889-B1	Beta-Lactam Antibiotic	1	0	1	0.68	0	0
Pen.	RDKit 0	19	14829431	US-4159272-A	Beta-Lactam Antibiotic	1	0	1	0.9	0	0
Pen.	RDKit 0	20	5046855	n/a	n/a	0	0	0	0.82	0	0
Pen.	RDKit n	1	108789963	n/a	n/a	0	0	0	0.9	0	0
Pen.	RDKit n	2	108788832	n/a	n/a	0	0	0	0.81	0	0
Pen.	RDKit n	3	57624293	US-2009081766-A1	Beta-Lactam Antibiotic	1	0	1	0.49	1	0
Pen.	RDKit n	4	108795879	n/a	n/a	0	0	0	0.9	0	0
Pen.	RDKit n	5	20341961	US-4200572-A	Beta-Lactam Antibiotic	1	0	1	0.46	1	0
Pen.	RDKit n	6	203884	n/a	n/a	0	0	0	0.85	0	0
Pen.	RDKit n	7	44458116	n/a	n/a	0	0	0	0.82	0	0
Pen.	RDKit n	8	123234728	WO-2014138046-A1	Formyl Peptide Receptor Agonist	1	0	0	0.26	0	0
Pen.	RDKit n	9	59069194	US-6815440-B2	Metalloprotease Inhibitor	1	0	0	0.41	0	0
Pen.	RDKit n	10	50877043	n/a	n/a	0	0	0	0.31	0	0
Pen.	RDKit n	11	5211680	n/a	n/a	0	0	0	0.35	0	0
Pen.	RDKit n	12	3288488	n/a	n/a	0	0	0	0.33	0	0
Pen.	RDKit n	13	11047455	n/a	n/a	0	0	0	0.41	0	0
Pen.	RDKit n	14	11860261	n/a	n/a	0	0	0	0.26	0	0
Pen.	RDKit n	15	121879937	n/a	n/a	0	0	0	0.4	0	0
Pen.	RDKit n	16	72811315	US-2016039825-A1	S1P / ATX Receptor Agonist	1	0	0	0.4	0	0
Pen.	RDKit n	17	53715169	CA-2297988-A1	Metalloprotease Inhibitor	1	0	0	0.43	0	0
Pen.	RDKit n	18	56796420	n/a	n/a	0	0	0	0.26	0	0

Table S2: CheSS Top Results Information. Includes query, canonic	calization, search rank, PubChem CID, P	atent ID/DOI,	, functio	onal descript	tor, cate	gorized	
drug/dye-likeness based on functionality, same functionality categoriza	ation, fingerprint Tanimoto coefficient bet	ween query &	e result,	, categorized	Structu	rally Dist	inct
Functional Analogue (SDFA), categorized Non-Derivative Functional	l Analogue (NDFA).			-		-	
any Canon Dark CID Detent ID / DOI	Europeine al Deservinter	Dung	Dree	Sim Eur	Та	SDEA	N

Query	Canon.	Rank	CID	Patent ID / DOI	Functional Descriptor	Drug	Dye	Sim. Fun.	Tc	SDFA	NDFA
Pen.	RDKit n	19	59847560	n/a	n/a	0	0	0	0.24	0	0
Pen.	RDKit n	20	11859780	n/a	n/a	0	0	0	0.26	0	0
Pen.	OEChem	1	135259185	WO-2018134148-A1	MKNK Inhibitor	1	0	0	0.45	0	0
Pen.	OEChem	2	20559382	US-4304779-A	Beta-Lactam Antibiotic	1	0	1	0.54	1	0
Pen.	OEChem	3	53944004	US-4077967-A	Beta-Lactam Antibiotic	1	0	1	0.74	0	0
Pen.	OEChem	4	88832135	US-3954731-A	Beta-Lactam Antibiotic	1	0	1	0.8	0	0
Pen.	OEChem	5	20536617	US4333944A	Sedative	1	0	0	0.43	0	0
Pen.	OEChem	6	88762822	n/a	n/a	0	0	0	0.46	0	0
Pen.	OEChem	7	88151512	EP1091959B1	Sedative	1	0	0	0.44	0	0
Pen.	OEChem	8	140604038	US6342340	Dye	0	0	0	0.34	0	0
Pen.	OEChem	9	101392657	n/a	n/a	0	0	0	0.4	0	0
Pen.	OEChem	10	17176746	n/a	n/a	0	0	0	0.48	0	0
Pen.	OEChem	11	10001910	n/a	n/a	0	0	0	0.43	0	0
Pen.	OEChem	12	72736793	n/a	n/a	0	0	0	0.46	0	0
Pen.	OEChem	13	67836365	EP-0275888-A2\	Cardiovascular	1	0	0	0.42	0	0
Pen.	OEChem	14	59898268	US7173041B2/en	Topoisomerase Inhibitor	1	0	0	0.44	0	0
Pen.	OEChem	15	53877724	US-4077967-A	Beta-Lactam Antibiotic	1	0	1	0.8	0	0
Pen.	OEChem	16	88640462	WO-8807534-A1	Beta-Lactamase Inhibitor	1	0	1	0.57	1	0
Pen.	OEChem	17	24811111	n/a	n/a	0	0	0	0.48	0	0
Pen.	OEChem	18	86733573	US-3965111-A	Sedative	1	0	0	0.43	0	0
Pen.	OEChem	19	58637593	n/a	n/a	0	0	0	0.28	0	0
Pen.	OEChem	20	20559367	US-4304779-A	Beta-Lactam Antibiotic	1	0	1	0.55	1	0
Nir.	RDKit 0	1	89072452	US-7192957-B2	HCV Protease Inhibitor	1	0	1	0.75	0	0
Nir.	RDKit 0	2	513166	10.1021/ol035826v	HCV Protease Inhibitor	1	0	1	0.6	0	0
Nir.	RDKit 0	3	89032648	US-7579320-B2	IAP BIR Ligand	1	0	0	0.55	0	0
Nir.	RDKit 0	4	88251520	WO-2008141227-A1	HCV Protease Inhibitor	1	0	1	0.62	0	0
Nir.	RDKit 0	5	89128765	n/a	n/a	0	0	0	0.54	0	0
Nir.	RDKit 0	6	89386569	n/a	n/a	0	0	0	0.67	0	0
Nir.	RDKit 0	7	163831729	WO-2006113942-A2	Peptidase Inhibitor	1	0	1	0.73	0	0
Nir.	RDKit 0	8	58846078	US-2006276406-A1	HCV Protease Inhibitor	1	0	1	0.65	0	0
Nir.	RDKit 0	9	10146053	n/a	n/a	0	0	0	0.65	0	0
Nir.	RDKit 0	10	70672489	US-8067379-B2	HCV Protease Inhibitor	1	0	1	0.56	1	0
Nir.	RDKit 0	11	49777413	10.1021/jm9016027	HCV Protease Inhibitor	1	0	1	0.56	1	0
Nir.	RDKit 0	12	70332592	US-7192957-B2	HCV Protease Inhibitor	1	0	1	0.64	0	0
Nir.	RDKit 0	13	58799854	US-2006276406-A1	HCV Protease Inhibitor	1	0	1	0.63	0	0
Nir.	RDKit 0	14	11758272	US-2006276405-A1	HCV Protease Inhibitor	1	0	1	0.65	0	0
Nir.	RDKit 0	15	117757300	EP-1730110-B9	HCV Protease Inhibitor	1	Õ	1	0.61	0	0
Nir.	RDKit 0	16	70672229	US-8067379-B2	HCV Protease Inhibitor	1	0	1	0.6	0	0

Query	Canon.	Rank	CID	Patent ID / DOI	Functional Descriptor	Drug	Dye	Sim. Fun.	Тс	SDFA	NDFA
Nir.	RDKit 0	17	69712881	US-2004209897-A1	Kinase Inhibitor	1	0	0	0.34	0	0
Nir.	RDKit 0	18	58815070	US-2007042968-A1	HCV Protease Inhibitor	1	0	1	0.59	1	0
Nir.	RDKit 0	19	91211330	US-2006281689-A1	HCV Protease Inhibitor	1	0	1	0.56	1	0
Nir.	RDKit 0	20	57842534	US-7244721-B2	HCV Protease Inhibitor	1	0	1	0.59	1	0
Nir.	RDKit n	1	58799854	US-2006276406-A1	HCV Protease Inhibitor	1	0	1	0.63	0	0
Nir.	RDKit n	2	89386569	n/a	n/a	0	0	0	0.67	0	0
Nir.	RDKit n	3	58799868	US-2006276406-A1	HCV Protease Inhibitor	1	0	1	0.58	1	0
Nir.	RDKit n	4	58799834	US-2006276406-A1	HCV Protease Inhibitor	1	0	1	0.6	0	0
Nir.	RDKit n	5	58908615	US-7244721-B2	HCV Protease Inhibitor	1	0	1	0.66	0	0
Nir.	RDKit n	6	58815070	US-2007042968-A1	HCV Protease Inhibitor	1	0	1	0.59	1	0
Nir.	RDKit n	7	58845760	US-2006276405-A1	HCV Protease Inhibitor	1	0	1	0.68	0	0
Nir.	RDKit n	8	91211330	US-2006281689-A1	HCV Protease Inhibitor	1	0	1	0.56	1	0
Nir.	RDKit n	9	57842534	US-7244721-B2	HCV Protease Inhibitor	1	0	1	0.59	1	0
Nir.	RDKit n	10	89128765	n/a	n/a	0	0	0	0.54	0	0
Nir.	RDKit n	11	70332562	US-7759499-B2	HCV Protease Inhibitor	1	0	1	0.61	0	0
Nir.	RDKit n	12	58751308	US-2006252698-A1	Peptidase Inhibitor	1	0	1	0.65	0	0
Nir.	RDKit n	13	90824016	US-2006276406-A1	HCV Protease Inhibitor	1	0	1	0.55	1	0
Nir.	RDKit n	14	89072393	n/a	n/a	0	0	0	0.58	0	0
Nir.	RDKit n	15	58845752	US-2006276406-A1	HCV Protease Inhibitor	1	0	1	0.62	0	0
Nir.	RDKit n	16	10146053	n/a	n/a	0	0	0	0.65	0	0
Nir.	RDKit n	17	6483344	US-2006276406-A1	HCV Protease Inhibitor	1	0	1	0.62	0	0
Nir.	RDKit n	18	143314765	WO2006113942	Peptidase Inhibitor	1	0	1	0.61	0	0
Nir.	RDKit n	19	58821357	US-7192957-B2	HCV Protease Inhibitor	1	0	1	0.59	1	0
Nir.	RDKit n	20	58821916	US-7192957-B2	HCV Protease Inhibitor	1	0	1	0.55	1	0
Nir.	OEChem	1	123307518	WO-2013107405-A1	Dehydrogenase Inhibitor	1	0	0	0.4	0	0
Nir.	OEChem	2	87441437	CA-2757866-A1	Dehydrogenase Inhibitor	1	0	0	0.38	0	0
Nir.	OEChem	3	123215879	WO-2014089379-A1	ATR Kinase Inhibitor	1	0	0	0.44	0	0
Nir.	OEChem	4	5065329	n/a	n/a	0	0	0	0.37	0	0
Nir.	OEChem	5	71268558	US-2013053410-A1	MDM2 Inhibitor	1	0	0	0.4	0	0
Nir.	OEChem	6	53344667	n/a	n/a	0	0	0	0.36	0	0
Nir.	OEChem	7	58262781	US-2011117057-A1	HCV Protease Inhibitor	1	0	1	0.56	1	1
Nir.	OEChem	8	137371163	US-2019002436-A1	RSV Inhibitor	1	Õ	1	0.35	1	1
Nir.	OEChem	9	89114369	US-2012270838-A1	GPCR Agonist	1	0	0	0.37	0	0
Nir.	OEChem	10	11997330	n/a	n/a	0	0	0	0.37	0	0
Nir.	OEChem	11	123849611	WO-2011143521-A2	CD26 Inhibitor	1	Õ	Õ	0.41	0	Õ
Nir.	OEChem	12	130253486	US-9714243-B2	HIV Integrase Inhibitor	1	Õ	0	0.36	0	0
Nir.	OEChem	13	126592125	WO-2017025989-A1	Dehydrogenase Inhibitor	1	ŏ	Õ	0.34	Ő	Ő
Nir.	OEChem	14	67152605	US-2011118283-A1	MDM2 Inhibitor	1	Ō	0	0.39	0	Ō

Query	Canon.	Rank	CID	Patent ID / DOI	Functional Descriptor	Drug	Dye	Sim. Fun.	Тс	SDFA	NDFA
Nir.	OEChem	15	134321551	EP-2941432-B1	ATR Protein Kinase Inhibitor	1	0	0	0.46	0	0
Nir.	OEChem	16	155276168	EP-2970283-B1	Peptidase Inhibitor	1	0	1	0.44	1	1
Nir.	OEChem	17	70239211	WO-2010021680-A2	Aspartyl Protease Inhibitor	1	0	1	0.36	1	1
Nir.	OEChem	18	88630878	US-4889857-A	Antibiotic	1	0	0	0.37	0	0
Nir.	OEChem	19	91802477	WO-2010043893-A1	DNA Gyrase Inhibitor	1	0	0	0.38	0	0
Nir.	OEChem	20	49966021	n/a	n/a	0	0	0	0.35	0	0
Zid.	RDKit 0	1	44326539	10.1021/jm00113a016	HSV Inhibitor	1	0	1	0.54	1	0
Zid.	RDKit 0	2	57303117	US-5064946-A	HIV Antiviral	1	0	1	0.77	0	0
Zid.	RDKit 0	3	157607985	US-2013072458-A1	HIV Antiviral	1	0	1	0.89	0	0
Zid.	RDKit 0	4	71335580	n/a	n/a	0	0	0	0.73	0	0
Zid.	RDKit 0	5	21145774	10.1016/S0960-894X(01)80809-X	n/a	0	0	0	0.37	0	0
Zid.	RDKit 0	6	9816797	n/a	n/a	0	0	0	0.72	0	0
Zid.	RDKit 0	7	53721880	US-6040297-A	HIV Antiviral	1	0	1	0.86	0	0
Zid.	RDKit 0	8	464363	n/a	n/a	0	0	0	0.74	0	0
Zid.	RDKit 0	9	57085874	US-4681933-A	Antiviral	1	0	1	0.88	0	0
Zid.	RDKit 0	10	91933148	n/a	n/a	0	0	0	0.76	0	0
Zid.	RDKit 0	11	44286560	10.1021/jm9600095	HIV Antiviral	1	0	1	0.88	0	0
Zid.	RDKit 0	12	101438451	n/a	n/a	0	0	0	0.53	0	0
Zid.	RDKit 0	13	13989283	US-2005026902-A1	HIV Antiviral	1	0	1	0.77	0	0
Zid.	RDKit 0	14	129675745	10.1007/978-1-4615-2824-1 5	HIV Antiviral	1	0	1	0.69	0	0
Zid.	RDKit 0	15	10469965	n/a	n/a	0	0	0	0.44	0	0
Zid.	RDKit 0	16	451826	US-4681933-A	HIV Antiviral	1	0	1	0.79	0	0
Zid.	RDKit 0	17	12922948	n/a	n/a	0	0	0	0.49	0	0
Zid.	RDKit 0	18	20158804	US-2020399304-A1	HIV Antiviral	1	0	1	0.91	0	0
Zid.	RDKit 0	19	49769999	10.1021/jm070824s	HIV Antiviral	1	0	1	0.5	1	0
Zid.	RDKit 0	20	10332953	n/a	n/a	0	0	0	0.57	0	0
Zid.	RDKit n	1	10494229	n/a	n/a	0	0	0	0.73	0	0
Zid.	RDKit n	2	476466	10.1016/0968-0896(95)00030-k	HIV Antiviral	1	0	1	0.56	1	0
Zid.	RDKit n	3	102306428	n/a	n/a	0	0	0	0.29	0	0
Zid.	RDKit n	4	89763182	EP-2631239-A1	HIV/HCV Antiviral	1	0	1	0.55	1	0
Zid.	RDKit n	5	10501259	n/a	n/a	0	0	0	0.53	0	0
Zid.	RDKit n	6	89763189	EP-2631239-A1	HIV/HCV Antiviral	1	0	1	0.55	1	0
Zid.	RDKit n	7	162488274	US20210371447	n/a	0	0	0	0.6	0	0
Zid.	RDKit n	8	90085164	US-2014088117-A1	Kinase Inhibitor	1	0	0	0.36	0	0
Zid.	RDKit n	9	89670654	US-2013172402-A1	DNA-Binding Oligo	1	0	0	0.7	0	0
Zid.	RDKit n	10	25185465	US-2012070415-A1	Antiviral	1	0	1	0.54	1	0
Zid.	RDKit n	11	10618341	n/a	n/a	0	0	0	0.54	0	0
Zid.	RDKit n	12	89433120	US-2013064794-A1	HCV Antiviral	1	0	1	0.37	1	0

Table S2: CheSS Top Results Information. Includes query, canonicalization, search rank, PubChem CID, Patent ID/DOI, functional descriptor, categorized
drug/dye-likeness based on functionality, same functionality categorization, fingerprint Tanimoto coefficient between query & result, categorized Structurally Distinct
Functional Analogue (SDFA), categorized Non-Derivative Functional Analogue (NDFA).

Query	Canon.	Rank	CID	Patent ID / DOI	Functional Descriptor	Drug	Dye	Sim. Fun.	Тс	SDFA	NDFA
Zid.	RDKit n	13	135016033	10.1055/s-0029-1217566	n/a	0	0	0	0.35	0	0
Zid.	RDKit n	14	124122254	AU-2015220560-B2	Kinase Inhibitor	1	0	0	0.31	0	0
Zid.	RDKit n	15	71834937	n/a	n/a	0	0	0	0.78	0	0
Zid.	RDKit n	16	23384164	US-2002028933-A1	Inflammation Treatment	1	0	0	0.25	0	0
Zid.	RDKit n	17	122418602	WO-2016113335-A1	Galectin Binding Inhibitor	1	0	0	0.32	0	0
Zid.	RDKit n	18	57155433	WO-9961583-A2	n/a	0	0	0	0.39	0	0
Zid.	RDKit n	19	117680541	US-2012070415-A1	Antiviral	1	0	1	0.38	1	0
Zid.	RDKit n	20	71477389	n/a	n/a	0	0	0	0.37	0	0
Zid.	OEChem	1	101424608	n/a	n/a	0	0	0	0.69	0	0
Zid.	OEChem	2	76847725	n/a	n/a	0	0	0	0.3	0	0
Zid.	OEChem	3	56679233	ES-2458358-T3	HCV Antiviral	1	0	1	0.33	1	0
Zid.	OEChem	4	89479439	EP-2760857-A1	PIM Kinase Inhibitor	1	0	0	0.35	0	0
Zid.	OEChem	5	90445142	US-2014271547-A1	HCV Antiviral	1	0	1	0.68	0	0
Zid.	OEChem	6	130375412	US-10449144-B2	n/a*	1	0	0	0.33	0	0
Zid.	OEChem	7	57284777	US-5585373-A	Anticancer Agent	1	0	0	0.36	0	0
Zid.	OEChem	8	57155433	WO1999061583A2	Carbohydrate Scaffold	0	0	0	0.39	0	0
Zid.	OEChem	9	10594262	n/a	n/a	0	0	0	0.34	0	0
Zid.	OEChem	10	136288884	n/a	n/a	0	0	0	0.36	0	0
Zid.	OEChem	11	102576629	n/a	n/a	0	0	0	0.29	0	0
Zid.	OEChem	12	88490101	EP-0236074-A1	Beta-Lactam Inhibitor	1	0	0	0.35	0	0
Zid.	OEChem	13	57103302	EP-0351021-A2	Herbicide	1	0	0	0.25	0	0
Zid.	OEChem	14	68220216	US-8034812-B2	Kinase Inhibitor	1	0	0	0.25	0	0
Zid.	OEChem	15	19967798	EP-0729070-A3	Industrial	0	1	0	0.24	0	0
Zid.	OEChem	16	68220235	US-8034812-B2	Kinase Inhibitor	1	0	0	0.24	0	0
Zid.	OEChem	17	117680541	US-2012070415-A1	RSV/Influenaza Antiviral	1	0	1	0.38	1	0
Zid.	OEChem	18	6333312	n/a	n/a	0	0	0	0.36	0	0
Zid.	OEChem	19	130290413	US-2017216275-A1	Phosphodiesterase Inhibitor	1	0	0	0.38	0	0
Zid.	OEChem	20	23519654	US-2003236216-A1	HCV Antiviral	1	0	1	0.57	1	0
LSD	RDKit 0	1	3938	WO-2020068832-A1	Dopaminergic Agonist	1	0	1	0.79	0	0
LSD	RDKit 0	2	165200	US-2023026731-A1	LSD Derivative	1	0	1	0.92	0	0
LSD	RDKit 0	3	56988771	DE-2924102-A1	Dopaminergic Agonist	1	0	1	0.79	0	0
LSD	RDKit 0	4	9884289	n/a	n/a	0	0	0	0.6	0	0
LSD	RDKit 0	5	134553	US20220096504	LSD Derivative	1	0	1	0.97	0	0
LSD	RDKit 0	6	24837792	US-3944582-A	LSD Derivative	1	0	0	0.59	0	0
LSD	RDKit 0	7	10427207	10.1021/jm00006a015	LSD Derivative	1	0	1	0.97	0	0
LSD	RDKit 0	8	13059865	US-4853390-A	Antidopaminergic	1	0	1	0.8	0	0
LSD	RDKit 0	9	76683560	US-2017174684-A1	Dopaminergic Agonist	1	0	1	0.89	0	0
LSD	RDKit 0	10	130318308	US9777016B2	5HT / Dopaminergic	1	0	1	0.77	0	0

Query	Canon.	Rank	CID	Patent ID / DOI	Functional Descriptor	Drug	Dye	Sim. Fun.	Тс	SDFA	NDFA
LSD	RDKit 0	11	13770164	US-4826852-A	Dopaminergic	1	0	1	0.73	0	0
LSD	RDKit 0	12	45357584	n/a	n/a	0	0	0	0.59	0	0
LSD	RDKit 0	13	3039342	Book	see PubChem	1	0	1	0.85	0	0
LSD	RDKit 0	14	13823178	US-4863929-A	Antidopaminergic	1	0	1	0.57	1	0
LSD	RDKit 0	15	67937682	US-4863929-A	Antidopaminergic	1	0	1	0.57	1	0
LSD	RDKit 0	16	88985978	WO2011003988A1	Somatic cell self renewel	1	0	0	0.88	0	0
LSD	RDKit 0	17	70430592	n/a	n/a	0	0	0	0.81	0	0
LSD	RDKit 0	18	57175320	US4348392A	Dopaminergic	1	0	1	0.56	1	0
LSD	RDKit 0	19	13192408	US-4826852-A	Dopaminergic	1	0	1	0.78	0	0
LSD	RDKit 0	20	13192405	US-4826852-A	Dopaminergic	1	0	1	0.78	0	0
LSD	RDKit n	1	44457782	US-2021346346-A1	Serotonergic Agonist	1	0	1	0.58	1	0
LSD	RDKit n	2	132584757	n/a	n/a	0	0	0	0.52	0	0
LSD	RDKit n	3	3058122	n/a	n/a	0	0	0	0.57	0	0
LSD	RDKit n	4	10640901	n/a	n/a	0	0	0	0.54	0	0
LSD	RDKit n	5	67938090	EP-0220129-B1	Dopaminergic Agonist	1	0	1	0.57	1	0
LSD	RDKit n	6	14723139	US-5411966-A	Dopaminergic Agonist	1	0	1	0.57	1	0
LSD	RDKit n	7	58459676	US-9730923-B2	Dopaminergic Agonist	1	0	1	0.3	1	1
LSD	RDKit n	8	4371364	n/a	n/a	0	0	0	0.51	0	0
LSD	RDKit n	9	67821466	n/a	n/a	0	0	0	0.48	0	0
LSD	RDKit n	10	68168631	US20120202823A1	Prodrug Carrier Moiety	1	0	0	0.35	0	0
LSD	RDKit n	11	56989523	n/a	Low-migration Coating	0	0	0	0.51	0	0
LSD	RDKit n	12	101648098	n/a	n/a	0	0	0	0.44	0	0
LSD	RDKit n	13	23621001	n/a	n/a	0	0	0	0.35	0	0
LSD	RDKit n	14	88840811	US3966706A	Dye	0	1	0	0.38	0	0
LSD	RDKit n	15	8882005	n/a	n/a	0	0	0	0.52	0	0
LSD	RDKit n	16	56843556	n/a	n/a	0	0	0	0.84	0	0
LSD	RDKit n	17	123178010	US20120177730A1	Chemosensory Receptor Ligand	1	0	0	0.54	0	0
LSD	RDKit n	18	101872812	n/a	n/a	0	0	0	0.45	0	0
LSD	RDKit n	19	126638676	WO-2017033019-A1	Kinase Inhibitor	1	0	0	0.5	0	0
LSD	RDKit n	20	57240530	US-5037832-A	Dopaminergic Agonist	1	0	1	0.72	0	0
LSD	OEChem	1	89651741	EP-2794606-A1	Neurodegen	1	0	0	0.41	0	0
LSD	OEChem	2	89705589	WO-2013107856-A1	Neurodegen	1	0	0	0.43	0	0
LSD	OEChem	3	3938	WO-2020068832-A1	LSD Derivative	1	0	1	0.79	0	0
LSD	OEChem	4	135838366	US-4696928-A	Anti-cancer	1	0	0	0.42	0	0
LSD	OEChem	5	129198569	EP-2888252-B1	Anti-Amyloid	1	0	0	0.38	0	0
LSD	OEChem	6	88368790	JPH0920755A/en	Alpha-1 receptor agonist	1	0	0	0.28	0	0
LSD	OEChem	7	89651520	EP-2794606-A1	Neurodegen	1	0	0	0.38	0	0
LSD	OEChem	8	18634859	US-4866057-A	Dopaminergic Agonist	1	0	1	0.39	1	1

Query	Canon.	Rank	CID	Patent ID / DOI	Functional Descriptor	Drug	Dye	Sim. Fun.	Tc	SDFA	NDFA
LSD	OEChem	9	9884289	n/a	LSD Derivative	0	0	0	0.6	0	0
LSD	OEChem	10	19850770	US-4866057-A	Dopaminergic Agonist	1	0	1	0.39	1	1
LSD	OEChem	11	129029504	WO-2017061957-A1	Methyltransferase Inhibitor	1	0	0	0.38	0	0
LSD	OEChem	12	69959271	US5126448A	Psychotropic	1	0	0	0.43	0	0
LSD	OEChem	13	23815464	n/a	n/a	0	0	0	0.44	0	0
LSD	OEChem	14	10621020	10.1021/jm9805687	5-HT1 Receptor Agonist	1	0	1	0.45	1	1
LSD	OEChem	15	56988771	DE-2924102-A1	LSD Derivative	1	0	1	0.79	0	0
LSD	OEChem	16	42609829	10.1038/nchembio.188	LSD Derivative	1	0	1	0.97	0	0
LSD	OEChem	17	123495938	WO-2013068470-A1	Neurological Treatment	1	0	0	0.46	0	0
LSD	OEChem	18	45124493	n/a	n/a	0	0	0	0.26	0	0
LSD	OEChem	19	13770164	US-4826852-A	LSD Derivative	1	0	1	0.73	0	0
LSD	OEChem	20	67563282	US-2010004226-A1	Anxiolytic	1	0	0	0.43	0	0
Fen.	RDKit 0	1	210867	US-RE29828-E	Analgesic	1	0	1	0.74	0	0
Fen.	RDKit 0	2	101682792	n/a	n/a	0	0	0	0.51	0	0
Fen.	RDKit 0	3	61996	WO-2021216450-A1	Mefentanyl	1	0	1	0.87	0	0
Fen.	RDKit 0	4	619324	n/a	n/a	0	0	0	0.79	0	0
Fen.	RDKit 0	5	21496449	US-3993762-A	Analgesic	1	0	1	0.63	0	0
Fen.	RDKit 0	6	7365707	n/a	n/a	0	0	0	0.81	0	0
Fen.	RDKit 0	7	12666095	10.1021/jm00182a016	Analgesic	1	0	1	0.75	0	0
Fen.	RDKit 0	8	451052	n/a	n/a	0	0	0	0.93	0	0
Fen.	RDKit 0	9	85863080	n/a	n/a	0	0	0	0.55	0	0
Fen.	RDKit 0	10	129522083	n/a	n/a	0	0	0	0.86	0	0
Fen.	RDKit 0	11	21951518	US-2014336214-A1	Analgesic	1	0	1	0.93	0	0
Fen.	RDKit 0	12	20068771	US-5100903-A	Analgesic	1	0	1	0.58	1	0
Fen.	RDKit 0	13	10499027	n/a	n/a	0	0	0	0.82	0	0
Fen.	RDKit 0	14	12741855	10.1021/jm00139a003	Analgesic	1	0	1	0.71	0	0
Fen.	RDKit 0	15	133809799	n/a	n/a	0	0	0	0.36	0	0
Fen.	RDKit 0	16	19902260	US-5100903-A	Analgesic	1	0	1	0.6	0	0
Fen.	RDKit 0	17	55456487	n/a	n/a	0	0	0	0.31	0	0
Fen.	RDKit 0	18	113074725	n/a	n/a	0	0	0	0.26	0	0
Fen.	RDKit 0	19	101682787	n/a	n/a	0	0	0	0.43	0	0
Fen.	RDKit 0	20	46048033	n/a	n/a	0	0	0	0.64	0	0
Fen.	RDKit n	1	46044596	n/a	n/a	0	0	0	0.22	0	0
Fen.	RDKit n	2	22503272	US-2004204421-A1	Serotonergic Agonist	1	0	0	0.25	0	0
Fen.	RDKit n	3	12298017	US-4179569-A	Analgesic	1	0	1	0.51	1	0
Fen.	RDKit n	4	15075634	n/a	n/a	0	0	0	0.81	0	0
Fen.	RDKit n	5	71258753	WO2013024291A2	Various Diseases	1	0	0	0.27	0	0
Fen.	RDKit n	6	57919355	US-2003236259-A1	Histamine H3 Agonist	1	0	0	0.28	0	0

Query	Canon.	Rank	CID	Patent ID / DOI	Functional Descriptor	Drug	Dye	Sim. Fun.	Tc	SDFA	NDFA
Fen.	RDKit n	7	91753695	n/a	n/a	0	0	0	0.81	0	0
Fen.	RDKit n	8	110408477	n/a	n/a	0	0	0	0.23	0	0
Fen.	RDKit n	9	57919390	US-2003236259-A1	Histamine H3 Agonist	1	0	0	0.27	0	0
Fen.	RDKit n	10	120540	10.1016/j.bmcl.2012.04.098	5-HTR1A Agonist	1	0	0	0.31	0	0
Fen.	RDKit n	11	46044468	n/a	n/a	0	0	0	0.19	0	0
Fen.	RDKit n	12	133342710	n/a	n/a	0	0	0	0.23	0	0
Fen.	RDKit n	13	133316530	n/a	n/a	0	0	0	0.24	0	0
Fen.	RDKit n	14	133282119	n/a	n/a	0	0	0	0.19	0	0
Fen.	RDKit n	15	68820800	US-2006122187-A1	Histamine H3 Agonist	1	0	0	0.22	0	0
Fen.	RDKit n	16	60716433	US-8420657-B2	Kinase Inhibitor	1	0	0	0.3	0	0
Fen.	RDKit n	17	90268870	WO-2014102590-A1	Analgesic	1	0	1	0.74	0	0
Fen.	RDKit n	18	46208762	WO-2010057833-A1	Muscular Dystrophy Treatment	1	0	0	0.23	0	0
Fen.	RDKit n	19	23961496	n/a	n/a	0	0	0	0.24	0	0
Fen.	RDKit n	20	46213640	KR-100990872-B1	Muscarinic Receptor Agonist	1	0	1	0.2	1	1
Fen.	OEChem	1	123511870	WO-2012113860-A2	Photosensitiziing Antibiotic	1	1	0	0.21	0	0
Fen.	OEChem	2	87843970	US-7074779-B2	Estrogen Receptor Modulator	1	0	0	0.16	0	0
Fen.	OEChem	3	57150779	WO-9740051-A1	Antihyperlipidemic Agent	1	0	0	0.24	0	0
Fen.	OEChem	4	57343443	n/a	n/a	0	0	0	0.26	0	0
Fen.	OEChem	5	19769681	US-5202333-A	5-HT3 Agonist	1	0	0	0.25	0	0
Fen.	OEChem	6	53890204	US4616023A	Calcium Channel Inhibitor	1	0	0	0.21	0	0
Fen.	OEChem	7	130393870	EP-2797921-B1	PARP Inhibitor	1	0	0	0.25	0	0
Fen.	OEChem	8	123921833	WO2013127266A1	NAMPT Inhibitor	1	0	0	0.22	0	0
Fen.	OEChem	9	88122657	US4885278A/en	Psychoactive (nonspecific)	1	0	0	0.21	0	0
Fen.	OEChem	10	70137168	WO-9965910-A1	Kinase Inhibitor	1	0	0	0.24	0	0
Fen.	OEChem	11	70633255	US4054569A	CNS Depressant	1	0	0	0.2	0	0
Fen.	OEChem	12	123142262	WO2012006321A2	Antibacterial	1	0	0	0.18	0	0
Fen.	OEChem	13	74349214	n/a	n/a	0	0	0	0.32	0	0
Fen.	OEChem	14	88208824	WO2000042045A2	Chemokine Receptor Mod.	1	0	0	0.24	0	0
Fen.	OEChem	15	100937756	n/a	n/a	0	0	0	0.19	0	0
Fen.	OEChem	16	70204314	EP0820450B1	C-Fiber Analgesic	1	0	0	0.21	0	0
Fen.	OEChem	17	68869271	US-2009143392-A1	PDE10a Inhibitor	1	0	0	0.24	0	0
Fen.	OEChem	18	18597963	US-4515949-A	Hypertension	1	0	0	0.25	0	0
Fen.	OEChem	19	163122578	n/a	n/a	0	0	0	0.26	0	0
Fen.	OEChem	20	88209026	WO2000042045A2	Chemokine Receptor Mod.	1	0	0	0.24	0	0
AB25	RDKit 0	1	53758252	US-3963763-A	Dye	0	1	1	0.69	0	0
AB25	RDKit 0	2	20658940	US-6241789-B1	Dye	0	1	1	0.78	0	0
AB25	RDKit 0	3	20314677	US-RE29724-E	Dye	0	1	1	0.62	0	0
AB25	RDKit 0	4	28468134	US3211755A	Dye	0	1	1	0.52	1	0

Table S2: CheSS Top Results Information. Includes query, canonicalization, search rank, PubChem CID, Patent ID/DOI, functional descriptor, categorized
drug/dye-likeness based on functionality, same functionality categorization, fingerprint Tanimoto coefficient between query & result, categorized Structurally Distinct
Functional Analogue (SDFA), categorized Non-Derivative Functional Analogue (NDFA).

Query	Canon.	Rank	CID	Patent ID / DOI	Functional Descriptor	Drug	Dye	Sim. Fun.	Tc	SDFA	NDFA
AB25	RDKit 0	5	123191991	WO-2012035122-A1	Dye	0	1	1	0.81	0	0
AB25	RDKit 0	6	88847454	US-3763159-A	Dye	0	1	1	0.89	0	0
AB25	RDKit 0	7	80836	US5385842A	Bacterial Sulfide Inhibitor	1	0	0	0.76	0	0
AB25	RDKit 0	8	23316284	US-4596666-A	Dye	0	1	1	0.51	1	0
AB25	RDKit 0	9	117662018	US-9228063-B2	Dye	0	1	1	0.51	1	0
AB25	RDKit 0	10	118582126	US-2021060995-A1	Dye	0	1	1	0.5	1	0
AB25	RDKit 0	11	3100898	US-4191566-A	Dye	0	1	1	0.64	0	0
AB25	RDKit 0	12	23454406	US-4276213-A	Dye	0	1	1	0.51	1	0
AB25	RDKit 0	13	20136182	US-4749521-A	Dye	0	1	1	0.77	0	0
AB25	RDKit 0	14	12260350	CN-103965648-A	Dye	0	1	1	0.73	0	0
AB25	RDKit 0	15	57573599	US-2009166583-A1	Dye	0	1	1	0.77	0	0
AB25	RDKit 0	16	19083394	US-5759211-A	Dye	0	1	1	0.79	0	0
AB25	RDKit 0	17	154153477	US-3324150-A	Dye	0	1	1	0.76	0	0
AB25	RDKit 0	18	21195065	US-5973038-A	Dye	0	1	1	0.6	0	0
AB25	RDKit 0	19	5027999	n/a	n/a	0	0	0	0.6	0	0
AB25	RDKit 0	20	129772523	10.1134/S0026261713040140	Dye	0	1	1	0.51	1	0
AB25	RDKit n	1	16205090	DE-1644589-B2	Dye	0	1	1	0.61	0	0
AB25	RDKit n	2	59123478	US-2003231237-A1	Dye	0	1	1	0.65	0	0
AB25	RDKit n	3	66487	US-6140517-A	Dye	0	1	1	0.59	1	0
AB25	RDKit n	4	22975881	US-2003110581-A1	Dye	0	1	1	0.62	0	0
AB25	RDKit n	5	71451728	n/a	n/a	0	0	0	0.64	0	0
AB25	RDKit n	6	70619779	US-4128396-A	Dye	0	1	1	0.59	1	0
AB25	RDKit n	7	89357654	WO2007053227A1	Dye	0	1	1	0.71	0	0
AB25	RDKit n	8	101530693	n/a	n/a	0	0	0	0.57	0	0
AB25	RDKit n	9	91433520	10.1016/j.jphotobiol.2010.08.010	Fluorescence Probe	0	1	1	0.37	1	1
AB25	RDKit n	10	22918414	US-5663336-A	Kinase Inhibitor	1	0	0	0.33	0	0
AB25	RDKit n	11	134848698	n/a	n/a	0	0	0	0.4	0	0
AB25	RDKit n	12	5483103	US-2015225584-A1	Dye	0	1	1	0.57	1	0
AB25	RDKit n	13	86048149	n/a	n/a	0	0	0	0.62	0	0
AB25	RDKit n	14	137212270	n/a	n/a	0	0	0	0.45	0	0
AB25	RDKit n	15	1727626	n/a	n/a	0	0	0	0.47	0	0
AB25	RDKit n	16	101530913	n/a	n/a	0	0	0	0.47	0	0
AB25	RDKit n	17	105919	n/a	n/a	0	0	0	0.39	0	0
AB25	RDKit n	18	1992311	n/a	n/a	0	0	0	0.46	0	0
AB25	RDKit n	19	1914542	n/a	n/a	0	0	0	0.46	0	0
AB25	RDKit n	20	117567	JP-2009072919-A	Dye	0	1	1	0.6	0	0
AB25	OEChem	1	102017117	n/a	n/a	0	0	0	0.39	0	0
AB25	OEChem	2	10895852	CN-108715591-A	Dye	0	1	1	0.36	1	1

Query	Canon.	Rank	CID	Patent ID / DOI	Functional Descriptor	Drug	Dye	Sim. Fun.	Tc	SDFA	NDFA
AB25	OEChem	3	10178481	US6919448B2	Dye	0	1	1	0.32	1	1
AB25	OEChem	4	136132324	US-2005020559-A1	Photosensitizing Agent	1	1	1	0.44	1	1
AB25	OEChem	5	90309725	EP-2159227-B1	Dye	0	1	1	0.2	1	1
AB25	OEChem	6	4426440	US20100055044A1	Anticancer (ETC Inhibitor)	1	0	0	0.41	0	0
AB25	OEChem	7	67741728	US-5382662-A	Catalyst	0	0	0	0.19	0	0
AB25	OEChem	8	68519583	US20100009927A1	Anti-inflammatory	1	0	0	0.18	0	0
AB25	OEChem	9	69299605	n/a	n/a	0	0	0	0.2	0	0
AB25	OEChem	10	136003417	n/a	n/a	0	0	0	0.29	0	0
AB25	OEChem	11	101659428	n/a	n/a	0	0	0	0.39	0	0
AB25	OEChem	12	136851558	n/a	n/a	0	0	0	0.44	0	0
AB25	OEChem	13	54159364	US-2015209428-A1	Photosensitizing Agent	1	1	1	0.33	1	1
AB25	OEChem	14	91212111	WO2010011959A1	Antiviral	1	0	0	0.43	0	0
AB25	OEChem	15	66696851	WO-2009100800-A1	Fluroescent	0	1	1	0.26	1	1
AB25	OEChem	16	136079295	WO-2009099673-A1	Electron Transfer	0	1	0	0.3	0	0
AB25	OEChem	17	69636218	WO2006015714A1	Optical Data Carrier	0	1	1	0.25	1	1
AB25	OEChem	18	66835451	WO-2006007184-A1	Phosphorescent	0	1	1	0.29	1	1
AB25	OEChem	19	69328133	US-6916799-B2	Ionophore	1	0	0	0.33	0	0
AB25	OEChem	20	91003879	US-6423469-B1	Dye	0	1	1	0.4	1	1
Avo	RDKit 0	1	69397178	EP-1181000-B1	Sunscreen	0	1	1	0.74	0	0
Avo	RDKit 0	2	39444601	n/a	n/a	0	0	0	0.52	0	0
Avo	RDKit 0	3	56836196	EP2600854B1/de	Sunscreen	0	1	1	0.93	0	0
Avo	RDKit 0	4	n/a	n/a	n/a	0	0	0	0.41	0	0
Avo	RDKit 0	5	131632684	n/a	n/a	0	0	0	0.54	0	0
Avo	RDKit 0	6	n/a	n/a	n/a	0	0	0	0.35	0	0
Avo	RDKit 0	7	81633789	n/a	n/a	0	0	0	0.29	0	0
Avo	RDKit 0	8	102107511	n/a	n/a	0	0	0	0.43	0	0
Avo	RDKit 0	9	8862174	n/a	n/a	0	0	0	0.45	0	0
Avo	RDKit 0	10	67831086	WO-9116034-A1	Sunscreen	0	1	1	0.9	0	0
Avo	RDKit 0	11	43337768	n/a	n/a	0	0	0	0.49	0	0
Avo	RDKit 0	12	18428769	US-6448304-B1	UV Absorbtion	0	1	1	0.81	0	0
Avo	RDKit 0	13	n/a	n/a	n/a	0	0	0	0.45	0	0
Avo	RDKit 0	14	43321130	n/a	n/a	0	0	0	0.55	0	0
Avo	RDKit 0	15	72034670	n/a	n/a	0	0	0	0.44	0	0
Avo	RDKit 0	16	105089397	n/a	n/a	0	0	0	0.3	0	0
Avo	RDKit 0	17	56836133	WO-2012016619-A1	Sunscreen	0	1	1	0.73	0	0
Avo	RDKit 0	18	63411706	n/a	n/a	0	0	0	0.38	0	0
Avo	RDKit 0	19	115781741	n/a	n/a	0	0	0	0.38	0	0
Avo	RDKit 0	20	43625029	US-2018085348-A1	RORI Inhibitor Anticancer	1	0	0	0.55	0	0

Query	Canon.	Rank	CID	Patent ID / DOI	Functional Descriptor	Drug	Dye	Sim. Fun.	Тс	SDFA	NDFA
Avo	RDKit n	1	102420223	US20230113128	Skin Protectant	0	1	1	0.75	0	0
Avo	RDKit n	2	123816547	US-2018155288-A1	UV Absorbing	0	1	1	0.73	0	0
Avo	RDKit n	3	89752401	n/a	n/a	0	0	0	0.41	0	0
Avo	RDKit n	4	69262951	WO-9423693-A1	UV Absorbing	0	1	1	0.67	0	0
Avo	RDKit n	5	89601532	US20140323376A1	Microcapsules	0	1	0	0.37	0	0
Avo	RDKit n	6	10592228	n/a	n/a	0	0	0	0.65	0	0
Avo	RDKit n	7	102454724	n/a	n/a	0	0	0	0.37	0	0
Avo	RDKit n	8	66756943	US-8119107-B2	UV Absorbing	0	1	1	0.61	0	0
Avo	RDKit n	9	15262337	n/a	n/a	0	0	0	0.52	0	0
Avo	RDKit n	10	121423935	US9452220B2	n/a	0	0	0	0.33	0	0
Avo	RDKit n	11	9857795	n/a	n/a	0	0	0	0.58	0	0
Avo	RDKit n	12	134950302	n/a	n/a	0	0	0	0.25	0	0
Avo	RDKit n	13	89393392	US-8362177-B1	Refractive Copolymer	0	1	1	0.27	1	1
Avo	RDKit n	14	18370144	US-6348617-B1	Pyruvate Purification	0	0	0	0.35	0	0
Avo	RDKit n	15	237566	n/a	n/a	0	0	0	0.28	0	0
Avo	RDKit n	16	62393856	n/a	n/a	0	0	0	0.32	0	0
Avo	RDKit n	17	117535120	n/a	n/a	0	0	0	0.36	0	0
Avo	RDKit n	18	69247116	n/a	Synthesis-Like Patents	0	0	0	0.41	0	0
Avo	RDKit n	19	62745021	n/a	n/a	0	0	0	0.51	0	0
Avo	RDKit n	20	67376073	WO-2004105712-A1	Sunscreen	0	1	1	0.84	0	0
Avo	OEChem	1	90148382	US-9059408-B2	Semiconductor	0	1	0	0.12	0	0
Avo	OEChem	2	89110687	WO-2010003533-A2	Tubercular Antibacterial	1	0	0	0.13	0	0
Avo	OEChem	3	88264669	EP-2388002-A2	Antidepressant	1	0	0	0.14	0	0
Avo	OEChem	4	123262979	WO-2012084941-A1	Photovoltaic	0	1	1	0.08	1	1
Avo	OEChem	5	102300581	n/a	n/a	0	0	0	0.12	0	0
Avo	OEChem	6	101259804	n/a	n/a	0	0	0	0.14	0	0
Avo	OEChem	7	88267104	n/a	n/a	0	0	0	0.14	0	0
Avo	OEChem	8	91595142	WO-2010050781-A1	Electroluminescent	0	1	1	0.12	1	1
Avo	OEChem	9	10266401	n/a	n/a	0	0	0	0.13	0	0
Avo	OEChem	10	58802136	US7176237B2	Many drug-like	1	0	0	0.1	0	0
Avo	OEChem	11	89652998	EP-1775335-B9	Electroluminescent	0	1	1	0.24	1	1
Avo	OEChem	12	101683095	n/a	n/a	0	0	0	0.12	0	0
Avo	OEChem	13	10945525	n/a	n/a	0	0	0	0.09	0	0
Avo	OEChem	14	57236739	US-4193931-A	Anti-Tumor	1	0	0	0.11	0	0
Avo	OEChem	15	123440338	WO2014086032A1	Kinase Inhibitor	1	0	0	0.12	0	0
Avo	OEChem	16	122224185	n/a	n/a	0	0	0	0.21	0	0
Avo	OEChem	17	23208426	EP0654488B1	Copolymer	0	0	0	0.11	0	0
Avo	OEChem	18	87402810	US20130023518A1	AMP Kinase Activator	1	0	0	0.2	0	0

Query	Canon.	Rank	CID	Patent ID / DOI	Functional Descriptor	Drug	Dye	Sim. Fun.	Tc	SDFA	NDFA
Avo	OEChem	19	68630174	EP-1641792-B1	PDE10A Inhibitor	1	0	0	0.15	0	0
Avo	OEChem	20	88746062	US-4011140-A	Anti-Tumor	1	0	0	0.13	0	0
2-dPAC	RDKit 0	1	118405815	US-2015280136-A1	Optoelectronic	0	1	1	0.28	1	0
2-dPAC	RDKit 0	2	57120863	US-2021135127-A1	Electroluminescent	0	1	1	0.28	1	1
2-dPAC	RDKit 0	3	117633923	EP-1802706-B1	Electroluminescent	0	1	1	0.26	1	0
2-dPAC	RDKit 0	4	57702177	US-2009131673-A1	Electroluminescent	0	1	1	0.18	1	0
2-dPAC	RDKit 0	5	58401023	n/a	n/a	0	0	0	0.18	0	0
2-dPAC	RDKit 0	6	135173910	US11289654B2/en	Optoelectronic	0	1	1	0.28	1	0
2-dPAC	RDKit 0	7	54511588	US-4931350-A	Electrophotographic	0	1	1	0.33	1	0
2-dPAC	RDKit 0	8	53473286	n/a	n/a	0	0	0	0.51	0	0
2-dPAC	RDKit 0	9	66650204	CN-114163447-A	Electroluminescent	0	1	1	0.43	1	0
2-dPAC	RDKit 0	10	85666158	US-2018040829-A1	Electroluminescent	0	1	1	0.27	1	0
2-dPAC	RDKit 0	11	118134114	US-2015162542-A1	Optoelectronic	0	1	1	0.22	1	0
2-dPAC	RDKit 0	12	15641729	n/a	n/a	0	0	0	0.21	0	0
2-dPAC	RDKit 0	13	72736479	JP2014034654	Electrochromic	0	1	1	0.32	1	0
2-dPAC	RDKit 0	14	131980099	US-2017288148-A1	Electroluminescent	0	1	1	0.29	1	0
2-dPAC	RDKit 0	15	101115479	n/a	n/a	0	0	0	0.13	0	0
2-dPAC	RDKit 0	16	102333726	n/a	n/a	0	0	0	0.16	0	0
2-dPAC	RDKit 0	17	59133370	US-2018090687-A1	Electroluminescent	0	1	1	0.29	1	0
2-dPAC	RDKit 0	18	132502906	n/a	n/a	0	0	0	0.26	0	0
2-dPAC	RDKit 0	19	12505268	n/a	n/a	0	0	0	0.32	0	0
2-dPAC	RDKit 0	20	88364885	US-2012126180-A1	Electroluminescent	0	1	1	0.39	1	0
2-dPAC	RDKit n	1	10892657	n/a	n/a	0	0	0	0.15	0	0
2-dPAC	RDKit n	2	123135311	n/a	n/a	0	0	0	0.17	0	0
2-dPAC	RDKit n	3	122210717	n/a	n/a	0	0	0	0.15	0	0
2-dPAC	RDKit n	4	11810541	n/a	n/a	0	0	0	0.19	0	0
2-dPAC	RDKit n	5	121228673	WO-2021012717-A1	Antitumor	1	0	0	0.16	0	0
2-dPAC	RDKit n	6	12065985	n/a	n/a	0	0	0	0.25	0	0
2-dPAC	RDKit n	7	58966992	US-2007213327-A1	Kinase Inhibitor	1	0	0	0.15	0	0
2-dPAC	RDKit n	8	102163265	n/a	n/a	0	0	0	0.14	0	0
2-dPAC	RDKit n	9	68969564	US-2009326006-A1	Beta-Secretase Inhibitor	1	0	0	0.21	0	0
2-dPAC	RDKit n	10	71456541	n/a	n/a	0	0	0	0.14	0	0
2-dPAC	RDKit n	11	101082530	n/a	n/a	0	0	0	0.2	0	0
2-dPAC	RDKit n	12	9836049	n/a	n/a	0	0	0	0.23	0	0
2-dPAC	RDKit n	13	10585958	n/a	n/a	0	0	0	0.23	0	0
2-dPAC	RDKit n	14	134852402	n/a	n/a	0	0	0	0.16	0	0
2-dPAC	RDKit n	15	699711	n/a	n/a	0	0	0	0.17	0	0
2-dPAC	RDKit n	16	101767888	n/a	n/a	0	0	0	0.16	0	0

Query	Canon.	Rank	CID	Patent ID / DOI	Functional Descriptor	Drug	Dye	Sim. Fun.	Тс	SDFA	NDFA
2-dPAC	RDKit n	17	59699922	WO-2007106236-A2	Kinase Modulator	1	0	0	0.17	0	0
2-dPAC	RDKit n	18	102515925	n/a	n/a	0	0	0	0.18	0	0
2-dPAC	RDKit n	19	729459	n/a	n/a	0	0	0	0.18	0	0
2-dPAC	RDKit n	20	5378237	n/a	n/a	0	0	0	0.16	0	0
2-dPAC	OEChem	1	101378249	n/a	n/a	0	0	0	0.09	0	0
2-dPAC	OEChem	2	11374507	n/a	n/a	0	0	0	0.16	0	0
2-dPAC	OEChem	3	134982929	n/a	n/a	0	0	0	0.06	0	0
2-dPAC	OEChem	4	121277727	n/a	n/a	0	0	0	0.21	0	0
2-dPAC	OEChem	5	91515383	US-2004151944-A1	Electroluminescent	0	1	1	0.13	1	1
2-dPAC	OEChem	6	122204293	n/a	n/a	0	0	0	0.16	0	0
2-dPAC	OEChem	7	136880633	n/a	n/a	0	0	0	0.18	0	0
2-dPAC	OEChem	8	632403	n/a	n/a	0	0	0	0.07	0	0
2-dPAC	OEChem	9	10178481	US6919448B2	Dye	0	1	1	0.16	1	1
2-dPAC	OEChem	10	102090697	n/a	n/a	0	0	0	0.09	0	0
2-dPAC	OEChem	11	57599395	US-2006216621-A1	Electrophotographic	0	1	1	0.19	1	1
2-dPAC	OEChem	12	54275018	US-5041366-A	Electrophotographic	0	1	1	0.18	1	1
2-dPAC	OEChem	13	137052079	WO-2013105026-A1	Nanoparticle Carrier	0	0	0	0.08	0	0
2-dPAC	OEChem	14	89304021	EP-2535331-A1	Electroluminescent	0	1	1	0.18	1	1
2-dPAC	OEChem	15	124008654	WO-2013178041-A1	Electroluminescent	0	1	1	0.17	1	1
2-dPAC	OEChem	16	118122961	EP-2878599-A1	Electroluminescent	0	1	1	0.17	1	0
2-dPAC	OEChem	17	89296775	EP-2535331-A1	Electroluminescent	0	1	1	0.17	1	1
2-dPAC	OEChem	18	90180369	US-9899600-B2	Electroluminescent	0	1	1	0.19	1	1
2-dPAC	OEChem	19	136436068	n/a	n/a	0	0	0	0.19	0	0
2-dPAC	OEChem	20	60136245	US-2010314615-A1	Electroluminescent	0	1	1	0.19	1	1